Templates
| HTML | Name | Effective Date | Version Label | |
|---|---|---|---|---|
| Templates with direct association to a transaction | ||||
| CDA Document Level Template | ||||
| html |  XeH Clinical Document 2.16.840.1.113883.2.51.10.4
|
2021‑09‑07 16:23:15 | ||
| Header Template common to all the XeHealth specified documents (e.g., Laboratory report, Hospital Discharge report, etc ...) | ||||
| html | XeH Clinical Document 2.16.840.1.113883.3.1937.99.61.67.10.18
ref
sxehealth-
|
2020‑12‑09 11:45:40 | ||
| Header Template common to all the XeHealth specified documents (e.g., Laboratory report, Hospital Discharge report, etc ...) | ||||
| html | XeH Diagnostic Imaging Report 2.16.840.1.113883.2.51.10.2
|
2021‑06‑21 14:23:14 | 0.1 | |
| A Diagnostic Imaging Report (DIR) is a document that contains a consulting specialist’s interpretation of image data. It conveys the interpretation to the referring (ordering) physician and becomes pa... | ||||
| html |  XeH Diagnostic Imaging Report2 2.16.840.1.113883.2.51.10.45
|
2021‑11‑08 15:59:54 | DICOM-20150324 | |
| html | XeH Hospital Discharge Report 2.16.840.1.113883.2.51.10.12
|
2021‑09‑10 14:49:32 | 0.1 | |
| A hospital discharge is the formal release of a patient from a hospital after a procedure or course of treatment. A discharge occurs whenever a patient leaves because of finalization... | ||||
| html | XeH Imaging Report 2.16.840.1.113883.2.51.10.1.9.1
|
2021‑06‑22 14:23:06 | ||
| This CDA Imaging Report document template defines the report content and technical constraints for top level elements, attributes, sections, and entries to be used in imaging report instances. This te... | ||||
| html | XeH Laboratory Result Report 2.16.840.1.113883.2.51.10.33
|
2021‑10‑01 11:41:22 | 0.1 | |
| Sharing Laboratory Reports (XD-LAB) Content Module This Content Integration Profile describes a laboratory report as an electronic document to be published towards ... | ||||
| html | XeH RD Patient Summary 2.16.840.1.113883.2.51.10.13
|
2021‑09‑10 14:50:49 | 0.1 | |
| The International Patient Summary is a "Minimal and non-exhaustive Patient Summary, specialty-agnostic, condition-independent, but readily usable by all clinicians for the unsched... | ||||
| CDA Header Level Template | ||||
| html |  CDA AssignedEntity 2.16.840.1.113883.10.12.153
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA AssignedEntity (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA AssignedEntity SDTC 2.16.840.1.113883.10.12.653
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA AssignedEntity (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA authenticator 2.16.840.1.113883.10.12.107
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA authenticator (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Authorization 2.16.840.1.113883.10.12.114
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Authorization (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA component 2.16.840.1.113883.10.12.112
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA component (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA componentOf 2.16.840.1.113883.10.12.113
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA componentOf (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA dataEnterer 2.16.840.1.113883.10.12.103
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA dataEnterer (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA documentationOf 2.16.840.1.113883.10.12.110
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA documentationOf (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA informationRecipient 2.16.840.1.113883.10.12.105
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA informationRecipient (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA inFulfillmentOf 2.16.840.1.113883.10.12.109
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA inFulfillmentOf (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA legalAuthenticator 2.16.840.1.113883.10.12.106
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA legalAuthenticator (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Organization 2.16.840.1.113883.10.12.151
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Organization (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Organization SDTC 2.16.840.1.113883.10.12.651
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Organization (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA participant 2.16.840.1.113883.10.12.108
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA participant (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Person 2.16.840.1.113883.10.12.152
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Person (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Person SDTC 2.16.840.1.113883.10.12.652
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Person (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA relatedDocument 2.16.840.1.113883.10.12.111
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA relatedDocument (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | DICOM author 1.2.840.10008.9.1.10.4
ref
DICOM-
|
2021‑07‑30 07:23:35 | ||
| html | DICOM componentOf 1.2.840.10008.9.1.10.7
ref
DICOM-
|
2021‑07‑30 07:27:56 | ||
| html | DICOM custodian 1.2.840.10008.9.1.10.6
ref
DICOM-
|
2021‑07‑30 07:26:09 | ||
| html | DICOM dataEnterer 1.2.840.10008.9.1.10.11
ref
DICOM-
|
2021‑07‑30 07:32:15 | ||
| html | DICOM documentationOf 1.2.840.10008.9.1.10.9
ref
DICOM-
|
2021‑07‑30 07:30:24 | ||
| html | DICOM informationRecipient 1.2.840.10008.9.1.10.5
ref
DICOM-
|
2021‑07‑30 07:25:00 | ||
| html | DICOM inFullfilmentOf 1.2.840.10008.9.1.10.8
ref
DICOM-
|
2021‑07‑30 07:29:18 | ||
| html | DICOM legalAutheticator 1.2.840.10008.9.1.10.3
ref
DICOM-
|
2021‑07‑30 07:21:39 | ||
| html | DICOM participant 1.2.840.10008.9.1.10.10
ref
DICOM-
|
2021‑07‑30 07:31:18 | ||
| html | DICOM recordTarget 1.2.840.10008.9.1.10.2
ref
DICOM-
|
2021‑07‑30 07:13:20 | ||
| html | Human Patient 1.3.6.1.4.1.19376.1.3.3.1.1
ref
XDLAB-
|
2017‑06‑07 | 2017 | |
| ClinicalDocument/recordTarget SHALL be present and SHALL conform to the Human Patient, Non-Human Subject or Human Patient with Non-Human Subject templates defined below. There are three varieties of l... | ||||
| html |  IPS CDA documentationOf 2.16.840.1.113883.10.22.2.6
ref
hl7ips-
|
2017‑04‑12 | STU1 | |
| The documentationOf relationship in an International Patient Summary contains the representation of providers who are wholly or partially responsible for the safety and well-being of a subject of care... | ||||
| html | IPS CDA Organization 2.16.840.1.113883.10.22.9.1
ref
hl7ips-
|
2017‑04‑11 | STU1 | |
| This is a reusable template providing essential information for describing / identifying an organization. | ||||
| html | IPS CDA Person 2.16.840.1.113883.10.22.9.3
ref
hl7ips-
|
2017‑04‑12 | STU1 | |
| Person name | ||||
| html | IPS CDA relatedDocument 2.16.840.1.113883.10.22.2.7
ref
hl7ips-
|
2017‑04‑12 | STU1 | |
| An IPS may have three types of parent document: A superseded version that the present instance of the document wholly repla... | ||||
| html | IPS Patient Contacts 2.16.840.1.113883.10.22.2.5
ref
hl7ips-
|
2017‑04‑12 | STU1 | |
| The IPS may record several kinds of patient contacts, including parents, relatives, caregivers, and others related in some way to the patient. A patient contact may be an individual or an organization... | ||||
| html | Laboratory Performer 1.3.6.1.4.1.19376.1.3.3.1.7
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| Laboratory Performers SHALL be recorded as performers in the CDA Header as well as in the structured body as demonstrated in the figure below. Documentation of laboratory performers MAY be done in mul... | ||||
| html | Laboratory Results Validator 1.3.6.1.4.1.19376.1.3.3.1.5
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| The ClinicalDocument/authenticator element MAY be present. When present it represents the clinical expert who performed the clinical validation (see the entries “validator” and “clinical expert” in th... | ||||
| html | Non-Human Subject 1.3.6.1.4.1.19376.1.3.3.1.2
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| ClinicalDocument/recordTarget SHALL be present and SHALL conform to the Human Patient, Non-Human Subject or Human Patient with Non-Human Subject templates defined below. There are three varieties of l... | ||||
| html | Ordering Provider 1.3.6.1.4.1.19376.1.3.3.1.6
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| ClinicalDocument/participant(s) MAY be present. When present, this element SHALL be in accordance with the HL7 CDA R2 standard with a time element and further constrained by this specification to requ... | ||||
| html | XeH CDA author 2.16.840.1.113883.2.51.10.5
|
2021‑09‑07 16:27:01 | ||
| A CDA document shall have at least one author. Authors could be either human (ClinicalDocument/author/assignedAuthor/assignedPerson) either devices (ClinicalDocument/author/assignedA... | ||||
| html | XeH CDA author 2.16.840.1.113883.3.1937.99.61.67.10.2
ref
sxehealth-
|
2020‑10‑02 11:14:41 | wip | |
| A CDA document shall have at least one author. Authors could be either human (ClinicalDocument/author/assignedAuthor/assignedPerson) either devices (ClinicalDocument/author/assignedA... | ||||
| html | XeH CDA custodian 2.16.840.1.113883.2.51.10.6
|
2021‑09‑07 16:32:38 | ||
| The custodian element represents the organization that is in charge of maintaining and is entrusted with the care of the document. This information is required ... | ||||
| html | XeH CDA custodian 2.16.840.1.113883.3.1937.99.61.67.10.5
ref
sxehealth-
|
2020‑10‑02 14:20:40 | wip | |
| The custodian element represents the organization that is in charge of maintaining and is entrusted with the care of the document. This information is required ... | ||||
| html | XeH CDA dataEnterer 2.16.840.1.113883.2.51.10.7
|
2021‑09‑07 16:54:33 | ||
| The dataEnterer (Transcriptionist) r epresents the participant who has transformed a dictated note into text. | ||||
| html | XeH CDA dataEnterer 2.16.840.1.113883.3.1937.99.61.67.10.12
ref
sxehealth-
|
2020‑10‑28 10:08:54 | wip | |
| The dataEnterer (Transcriptionist) r epresents the participant who has transformed a dictated note into text. | ||||
| html | XeH CDA legalAuthenticator 2.16.840.1.113883.2.51.10.8
|
2021‑09‑07 16:56:24 | ||
| The legalAuthenticator identifies the single person legally responsible for the document and must be present if the document has been legally authenticated. A clinical document that ... | ||||
| html | XeH CDA legalAuthenticator 2.16.840.1.113883.3.1937.99.61.67.10.3
ref
sxehealth-
|
2020‑10‑02 11:16:10 | wip | |
| The legalAuthenticator identifies the single person legally responsible for the document and must be present if the document has been legally authenticated. A clinical document that ... | ||||
| html | XeH CDA Person 2.16.840.1.113883.2.51.10.72
|
2022‑05‑29 10:14:42 | ||
| Template CDA Person (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | XeH CDA Person 2.16.840.1.113883.2.51.10.73
|
2022‑05‑29 10:15:16 | ||
| XeH Person name | ||||
| html | XeH CDA recordTarget 2.16.840.1.113883.2.51.10.9
|
2021‑09‑07 18:24:22 | ||
| The recordTarget records the administrative and demographic data of the patient whose health information is described by the clinical document; each recordTarget must contain at least one patientRole ... | ||||
| html | XeH CDA recordTarget 2.16.840.1.113883.3.1937.99.61.67.10.1
ref
sxehealth-
|
2020‑09‑29 12:01:13 | wip | |
| The recordTarget records the administrative and demographic data of the patient whose health information is described by the clinical document; each recordTarget must contain at least one patientRole ... | ||||
| html | XeH CDA recordTarget with non-human Subject 2.16.840.1.113883.2.51.10.53
|
2022‑02‑16 10:08:09 | ||
| The recordTarget records the administrative and demographic data of the patient whose health information is described by the clinical document; each recordTarget must contain at least one patientRole ... | ||||
| html | XeH ComponentOf 2.16.840.1.113883.2.51.10.10
|
2021‑09‑07 18:27:26 | ||
| html | XeH ComponentOf 2.16.840.1.113883.3.1937.99.61.67.10.7
ref
sxehealth-
|
2020‑10‑02 14:47:14 | wip | |
| html | XeH DocumentationOf (report) 2.16.840.1.113883.3.1937.99.61.67.10.14
ref
sxehealth-
|
2020‑10‑28 12:24:01 | wip | |
| Content Modules for CDA Header (Level 1): Laboratory Performer template in the CDA header (ClinicalDocument/documentationOf/serviceEvent) ClinicalDocument/documenta... | ||||
| html | XeH HDR ComponentOf 2.16.840.1.113883.2.51.10.49
|
2021‑12‑03 11:50:16 | ||
| html | XeH Header 2.16.840.1.113883.2.51.10.1.2.1
|
2021‑06‑30 12:15:42 | ||
| Header Template common to all the XeHealth specified documents (e.g., Laboratory report, Hospital Discharge report, etc ...) | ||||
| html | XeH Information Recipient 2.16.840.1.113883.2.51.10.14
|
2021‑09‑10 14:59:36 | ||
| ClinicalDocument/informationRecipient MAY be present. When present, it SHALL be in accordance with the HL7 CDA R2 standard and further constrained by this specification to require the presence of name... | ||||
| html | XeH Information Recipient 2.16.840.1.113883.3.1937.99.61.67.10.15
ref
sxehealth-
|
2020‑10‑28 12:35:19 | wip | |
| ClinicalDocument/informationRecipient MAY be present. When present, it SHALL be in accordance with the HL7 CDA R2 standard and further constrained by this specification to require the presence of name... | ||||
| html | XeH inFulfillmentOf 2.16.840.1.113883.2.51.10.11
|
2021‑09‑07 18:41:24 | ||
| eHDSI Template CDA inFulfillmentOf (prototype, directly derived from POCD_RM000040 MIF) XD-lab ... | ||||
| html | XeH Lab ComponentOf 2.16.840.1.113883.2.51.10.71
|
2022‑05‑23 10:20:45 | ||
| html | XeH Lab DocumentationOf 2.16.840.1.113883.2.51.10.47
|
2021‑11‑29 17:16:55 | 2017 | |
| Content Modules for CDA Header (Level 1): Laboratory Performer template in the CDA header (ClinicalDocument/documentationOf/serviceEvent) ClinicalDocument/documenta... | ||||
| html | XeH Ordering Provider 2.16.840.1.113883.2.51.10.48
|
2021‑11‑29 17:36:33 | ||
| XeH Ordering Provider | ||||
| html | XeH Ordering Provider2 2.16.840.1.113883.2.51.10.1.2.2
|
2021‑11‑29 17:41:01 | ||
| ClinicalDocument/participant(s) MAY be present. When present, this element SHALL be in accordance with the HL7 CDA R2 standard with a time element and further constrained by this specification to requ... | ||||
| html | XeH Ordering/Referring Provider 2.16.840.1.113883.3.1937.99.61.67.10.4
ref
sxehealth-
|
2020‑10‑02 11:27:37 | wip | |
| Header participant representing any ordering provider or referring physician for this document, e.g. : the ordering provider of the order (or group of orders) f... | ||||
| html | XeH Results Validator 2.16.840.1.113883.2.51.10.44
|
2020‑10‑28 10:55:16 | ||
| The ClinicalDocument/authenticator element MAY be present. When present it represents the clinical expert who performed the clinical validation (see the entries “validator” and “clinical expert” in th... | ||||
| html | XeH Results Validator2 2.16.840.1.113883.2.51.10.74
|
2022‑05‑31 03:10:08 | ||
| The ClinicalDocument/authenticator element MAY be present. When present it represents the clinical expert who performed the clinical validation (see the entries “validator” and “clinical expert” in th... | ||||
| CDA Section Level Template | ||||
| html | Addendum 1.2.840.10008.9.6
ref
DICOM-
|
2021‑06‑22 12:04:38 | DICOM-20150324 | |
| Addendum section for imaging report includes supplemental information added to the original document contents. | ||||
| html | CDA Informant 2.16.840.1.113883.10.12.154
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Informant (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA NonXMLBody 2.16.840.1.113883.10.12.203
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA NonXMLBody (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Section 2.16.840.1.113883.10.12.201
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Section (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA StructuredBody 2.16.840.1.113883.10.12.202
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA StructuredBody (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | Clinical Information 1.2.840.10008.9.2
ref
DICOM-
|
2021‑06‑22 11:38:24 | DICOM-20150324 | |
| Clinical details about the case such as presenting signs and symptoms, past clinical history, the overall condition of the patient, etc | ||||
| html | Communication of Actionable Findings 1.2.840.10008.9.11
ref
DICOM-
|
2021‑06‑22 11:10:34 | DICOM-20150324 | |
| A section that documents the notification of an actionable finding to a provider or other person responsible for patient care. The documentation in narrative text, and optionally in a coded entry, inc... | ||||
| html | Comparison Study 1.2.840.10008.9.4
ref
DICOM-
|
2021‑06‑22 12:01:16 | DICOM-20150324 | |
| Documentation of a prior Imaging Procedure to which the current images were compared. | ||||
| html | Complications Section (V3) 2.16.840.1.113883.10.20.22.2.37
ref
ccda-
|
2015‑08‑01 | 2.1 | |
| This section contains problems that occurred during or around the time of a procedure. The complications may be known risks or unanticipated problems. | ||||
| html | DICOM Object Catalog Section - DCM 121181 2.16.840.1.113883.10.20.6.1.1
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| DICOM Object Catalog lists all referenced objects and their parent Series and Studies, plus other DICOM attributes required for retrieving the objects. DICOM Object Catalog sections are not intended f... | ||||
| html | Fetus Findings 1.2.840.10008.9.9
ref
DICOM-
|
2021‑06‑22 09:32:55 | DICOM-20150324 | |
| Records clinically significant observations confirmed or discovered during the procedure. | ||||
| html | Findings 2.16.840.1.113883.10.20.6.1.2
|
2021‑06‑22 12:11:39 | DICOM-20150324 | |
| Records clinically significant observations confirmed or discovered during the procedure. | ||||
| html | Hospital Discharge Studies Summary Section 2.16.840.1.113883.10.20.22.2.16
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This section records the results of observations generated by laboratories, imaging procedures, and other procedures. The scope includes hematology, chemistry, serology, virology, toxicology, microbio... | ||||
| html | IHE Payers section 1.3.6.1.4.1.19376.1.5.3.1.1.5.3.7
ref
IHE-PCC-
|
2015‑07‑02 21:32:44 | 2014 | |
| The Payers section contains data on the patient’s payers, whether a ‘third party’ insurance, self-pay, other payer or guarantor, or some combination. | ||||
| html | Imaging Procedure Description 1.2.840.10008.9.3
ref
DICOM-
|
2021‑06‑22 11:48:00 | DICOM-20150324 | |
| The Imaging Procedure Description section records the technical details of the procedure and may include information about protocol, imaging device, contrast, radiation dose, medications administered ... | ||||
| html | Impression 1.2.840.10008.9.5
ref
DICOM-
|
2021‑06‑22 12:22:26 | DICOM-20150324 | |
| The most important diagnoses or other clinical conclusions that can be made from the imaging observations and other clinical information are recorded here. This section may include recommendations for... | ||||
| html | IPS Advance Directives Section 2.16.840.1.113883.10.22.3.12
ref
hl7ips-
|
2020‑05‑08 16:38:49 | TI-2020 | |
| The advance directive section shall contain a narrative description of patient's advance directive. The optional author and informant elements are used when ne... | ||||
| html | IPS Allergies and Intolerances Section 2.16.840.1.113883.10.22.3.2
ref
hl7ips-
|
2016‑11‑11 | STU1 | |
| This section documents the relevant allergies or intolerances (conditions) for that patient, describing the kind of reaction (e.g. rash, anaphylaxis,..); preferably the agents that c... | ||||
| html | IPS Functional Status Section 2.16.840.1.113883.10.22.3.8
ref
hl7ips-
|
2020‑05‑08 19:17:37 | TI-2020 | |
| The functional status section shall contain a narrative description of capability of the patient to perform acts of daily living, including possible needs of the patient to be continuously assessed by... | ||||
| html | IPS History of Pregnancy Section 2.16.840.1.113883.10.22.3.11
ref
hl7ips-
|
2020‑05‑07 18:46:08 | TI-2020 | |
| The history of pregnancy section shall contain information about whether the patient is currently pregnant (optional with the Expected Delivery Date) or not. I... | ||||
| html | IPS History of Procedures Section 2.16.840.1.113883.10.22.3.4
ref
hl7ips-
|
2017‑03‑27 | STU1 | |
| The History of Procedures Section contains a description of the patient past procedures that are pertinent to the scope of this document. Procedu... | ||||
| html | IPS Medical Devices Section 2.16.840.1.113883.10.22.3.6
ref
hl7ips-
|
2021‑10‑20 17:11:42 | 2021 | |
| The medical devices section contains narrative text and coded entries describing the patient history of medical device use. Medical devices include, but are not limited to, implanted devices and devi... | ||||
| html | IPS Plan of Care Section 2.16.840.1.113883.10.22.3.9
ref
hl7ips-
|
2020‑05‑08 18:28:38 | TI-2020 | |
| The care plan section contains a narrative description of the expectations for care including proposals, goals, and order requests for monitoring, tracking, or improving the conditio... | ||||
| html | IPS Problems Section 2.16.840.1.113883.10.22.3.3
ref
hl7ips-
|
2017‑02‑15 | STU1 | |
| The IPS problem section lists and describes clinical problems or conditions currently being monitored for the patient. This section can record different kinds of problems as, but not limited to, chr... | ||||
| html | IPS Results Section 2.16.840.1.113883.10.22.3.14
ref
hl7ips-
|
2017‑04‑30 | STU1 | |
| This section assembles relevant observation results collected on the patient or produced on in-vitro biologic specimens collected from the patient. Some of these results may be laboratory results, oth... | ||||
| html | IPS Social History Section 2.16.840.1.113883.10.22.3.10
ref
hl7ips-
|
2020‑05‑10 18:52:32 | TI-2020 | |
| The social history section contains a description of the person’s Health related “lifestyle factors" or "lifestyle observations" (e.g. smoke habits; alcohol consumption; diets, risky habits.) The opti... | ||||
| html | IPS Translation Section 2.16.840.1.113883.10.22.3.15
ref
hl7ips-
|
2021‑09‑02 12:04:41 | 2021 | |
| Template CDA Section to carry the translations of a Parent Section | ||||
| html | Key Images 1.3.6.1.4.1.19376.1.4.1.2.14
ref
DICOM-
|
2021‑06‑22 11:51:27 | DICOM-20150324 | |
| The Key Images section contains narrative description of and references to DICOM Image Information Objects that illustrate the findings of the procedure reported. | ||||
| html | Labeled Subsection 1.2.840.10008.9.10
ref
DICOM-
|
2021‑06‑22 10:11:25 | DICOM-20150324 | |
| Narrative or coded subsection that allows organization of content for a labeled topic (a particular organ or anatomic feature, a lesion, a tumor, etc.). The section.code shall be absent, but the secti... | ||||
| html | Laboratory Report Item Section 1.3.6.1.4.1.19376.1.3.3.2.2
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| At the second level (nested in one specialty section), each leaf section represents a Report Item. It can be a battery (or test panel), an individual test, or the complete study of a specimen (particu... | ||||
| html | Medical (General) History Section 2.16.840.1.113883.10.20.22.2.39
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| The Medical History Section describes all aspects of the medical history of the patient even if not pertinent to the current procedure, and may include chief complaint, past medical history, social hi... | ||||
| html | Procedure Indications 1.2.840.10008.9.1.10.14
ref
DICOM-
|
2021‑10‑28 13:56:39 | DICOM-20150324 | |
| This section contains the reason(s) for the procedure or surgery. This section may include the preprocedure diagnoses as well as symptoms contributing to the reason for the procedure. | ||||
| html | Procedure Indications 2.16.840.1.113883.10.20.22.2.29
|
2021‑06‑21 16:23:58 | DICOM-20150324 | |
| Records details about the reason for the procedure. This section may include the pre-procedure diagnosis or diagnoses as well as one or more symptoms that contribute to the reason the procedure is bei... | ||||
| html | Radiation Exposure and Protection Information 1.2.840.10008.9.8
ref
DICOM-
|
2021‑06‑22 10:18:06 | DICOM-20150324 | |
| Contains information related to the radiation exposure and protection of the patient, as may be required by national or local legal requirements or standards. | ||||
| html | Recommendation 1.2.840.10008.9.12
ref
DICOM-
|
2021‑06‑22 12:18:21 | DICOM-20150324 | |
| This section provides a separate section to describe the study interpreter's recommendations for follow-up studies or procedures. | ||||
| html | Request 1.2.840.10008.9.7
ref
DICOM-
|
2021‑06‑21 15:52:41 | DICOM-20150324 | |
| Information about the requested imaging studies and associated tests. It may include information on the reason for the request, and on any validation of the request by clinical decision support agains... | ||||
| html | Test1 2.16.840.1.113883.2.51.10.1.3.1
|
2021‑06‑24 10:48:34 | ||
| Template for test presentation | ||||
| html | Test1 2.16.840.1.113883.2.51.10.1.3.2
|
2021‑06‑24 10:48:39 | ||
| Template for test presentation | ||||
| html | XeH Addendum 2.16.840.1.113883.2.51.10.87
|
2022‑07‑15 10:08:46 | DICOM-20150324 | |
| Addendum section for imaging report includes supplemental information added to the original document contents. | ||||
| html | XeH Admission Diagnosis Section 2.16.840.1.113883.2.51.10.29
|
2021‑10‑01 08:54:36 | 0.1 | |
| This section contains a narrative description of the problems or diagnoses identified by the clinician at the time of the patient’s admission. This section may contain coded entries representing the a... | ||||
| html | XeH Admission Medications Section 2.16.840.1.113883.2.51.10.31
|
2021‑10‑01 09:07:37 | 0.1 | |
| The section contains the medications taken by the patient prior to and at the time of admission to the facility. | ||||
| html | XeH Alerts Section 2.16.840.1.113883.2.51.10.17
|
2021‑09‑10 15:24:33 | 0.1 | |
| This section contains data describing an interest or worry about a health state or process that could possibly require attention, intervention, or management. A Health Concern is a health related matt... | ||||
| html | XeH Annotation Comment 2.16.840.1.113883.2.51.10.58
|
2022‑03‑03 11:24:50 | 0.1 | |
| html | XeH Care Team Section 2.16.840.1.113883.2.51.10.39
|
2021‑10‑19 09:35:03 | ||
| html | XeH Chief Complaint and Reason for Visit Section 2.16.840.1.113883.2.51.10.30
|
2021‑10‑01 09:02:36 | 0.1 | |
| This section records the patient's chief complaint (the patient’s own description) and/or the reason for the patient's visit (the provider’s description of the reason for visit). Local policy determin... | ||||
| html | XeH Clinical Information 2.16.840.1.113883.2.51.10.61
|
2022‑03‑17 11:51:55 | DICOM-20150324 | |
| Clinical details about the case such as presenting signs and symptoms, past clinical history, the overall condition of the patient, etc | ||||
| html | XeH Communication of Actionable Findings 2.16.840.1.113883.2.51.10.84
|
2022‑07‑12 08:30:50 | DICOM-20150324 | |
| A section that documents the notification of an actionable finding to a provider or other person responsible for patient care. The documentation in narrative text, and optionally in a coded entry, inc... | ||||
| html | XeH Comparison Study 2.16.840.1.113883.2.51.10.86
|
2022‑07‑15 10:02:06 | DICOM-20150324 | |
| Documentation of a prior Imaging Procedure to which the current images were compared. | ||||
| html | XeH Complications Section 2.16.840.1.113883.2.51.10.80
|
2022‑06‑24 11:20:43 | ||
| This section contains problems that occurred during or around the time of a procedure. The complications may be known risks or unanticipated problems. | ||||
| html | XeH Discharge Diagnosis Section 2.16.840.1.113883.2.51.10.28
|
2021‑10‑01 08:29:04 | ||
| The discharge diagnosis section shall contain a narrative description of the conditions that need to be monitored after discharge from the hospital and those that were resolved during the hospital cou... | ||||
| html | XeH Discharge Medications Section 2.16.840.1.113883.2.51.10.26
|
2021‑10‑01 08:14:14 | 0.1 | |
| This section contains the medications the patient is intended to take or stop after discharge. Current, active medications must be listed. The section may also include a patient’s prescription history... | ||||
| html | XeH Family History Section 2.16.840.1.113883.2.51.10.16
|
2021‑09‑10 15:22:07 | 0.1 | |
| This section contains data defining the patient’s genetic relatives in terms of possible or relevant health risk factors that have a potential impact on the patient’s healthcare risk profile. | ||||
| html | XeH Fetus Findings 2.16.840.1.113883.2.51.10.88
|
2022‑07‑15 10:52:20 | DICOM-20150324 | |
| Records clinically significant observations confirmed or discovered during the procedure. | ||||
| html | XeH Findings 2.16.840.1.113883.2.51.10.79
|
2022‑06‑24 08:53:12 | DICOM-20150324 | |
| The Findings section contains the main narrative body of the report. While not an absolute requirement for transformed DICOM SR reports, it is suggested that Diagnostic Imaging Reports authored in CDA... | ||||
| html | XeH Foreign Travel Section 2.16.840.1.113883.2.51.10.67
|
2022‑05‑06 10:13:31 | ||
| The foreign travel section contains only narrative text describing the patient's travel history. | ||||
| html | XeH History of Past Illness Section 2.16.840.1.113883.2.51.10.57
|
2022‑02‑18 09:12:34 | ||
| The History of Past Illness section contains a narrative description and coded entries of the conditions the patient suffered in the past. The optional author and informant elements are used when nec... | ||||
| html | XeH Hospital Course Section 2.16.840.1.113883.2.51.10.83
|
2022‑06‑24 15:29:00 | ||
| The hospital course section shall contain a narrative description of the sequence of events from admission to discharge in a hospital facility. | ||||
| html | XeH Hospital Discharge Physical Section 2.16.840.1.113883.2.51.10.50
|
2021‑12‑17 08:59:34 | ||
| The Hospital Discharge Physical Section records a narrative description of the patient’s physical findings. | ||||
| html | XeH Imaging Procedure Description 2.16.840.1.113883.2.51.10.63
|
2022‑03‑21 16:08:00 | DICOM-20150324 | |
| The Imaging Procedure Description section records the technical details of the procedure and may include information about protocol, imaging device, contrast, radiation dose, medications administered ... | ||||
| html | XeH Immunizations Section 2.16.840.1.113883.2.51.10.65
|
2022‑05‑06 09:34:10 | ||
| The Immunizations Section defines a patient's current immunization status and pertinent immunization history. The primary use case for the Immunization Section is to enable communication of a patient... | ||||
| html | XeH Impression 2.16.840.1.113883.2.51.10.85
|
2022‑07‑15 09:56:05 | DICOM-20150324 | |
| The most important diagnoses or other clinical conclusions that can be made from the imaging observations and other clinical information are recorded here. This section may include recommendations for... | ||||
| html | XeH Infectious Contact Section 2.16.840.1.113883.2.51.10.52
|
2022‑01‑14 10:50:11 | 0.1 | |
| This Section summarizes the exposures to potentially harmful entity of this subject. | ||||
| html | XeH Labeled Subsection 2.16.840.1.113883.2.51.10.89
|
2022‑07‑15 10:55:36 | DICOM-20150324 | |
| Narrative or coded subsection that allows organization of content for a labeled topic (a particular organ or anatomic feature, a lesion, a tumor, etc.). The section.code shall be absent, but the secti... | ||||
| html | XeH Laboratory Report Item Section 2.16.840.1.113883.2.51.10.55
|
2022‑02‑16 11:32:28 | 0.1 | |
| At the second level (nested in one specialty section), each leaf section represents a Report Item. It can be a battery (or test panel), an individual test, or the complete study of a specimen (particu... | ||||
| html | XeH Laboratory Specialty Section, Variant 1 2.16.840.1.113883.2.51.10.34
|
2021‑10‑01 12:00:38 | 0.1 | |
| Every Laboratory Report SHALL contain at least one Laboratory Specialty Section. Each top section represents a specialty. A laboratory report MAY be composed of test results from a single specialty (e... | ||||
| html | XeH Laboratory Specialty Section, Variant 2 2.16.840.1.113883.2.51.10.54
|
2022‑02‑16 10:55:28 | 0.1 | |
| Every Laboratory Report SHALL contain at least one Laboratory Specialty Section. Each top section represents a specialty. A laboratory report MAY be composed of test results from a single specialty (e... | ||||
| html | XeH Medication Summary Section 2.16.840.1.113883.2.51.10.41
|
2021‑10‑19 11:12:56 | ||
| The medication summary section contains a description of the patient's medications relevant for the scope of the patient summary. The actual content could depen... | ||||
| html | XeH Patient History Section 2.16.840.1.113883.2.51.10.15
|
2021‑09‑10 15:17:23 | 0.1 | |
| This Section describes all aspects of the medical history of the patient even if not pertinent to the current procedure, and may include chief complaint, past medical history, social history, family h... | ||||
| html | XeH Problems Section 2.16.840.1.113883.2.51.10.23
|
2021‑09‑22 17:29:31 | 0.1 | |
| The IPS problem section lists and describes clinical problems or conditions currently being monitored for the patient. This section can record different kinds of problems as, but not limited to, chr... | ||||
| html | XeH Procedure Indications 2.16.840.1.113883.2.51.10.77
|
2022‑06‑17 11:56:34 | DICOM-20150324 | |
| This section contains the reason(s) for the procedure or surgery. This section may include the preprocedure diagnoses as well as symptoms contributing to the reason for the procedure. | ||||
| html | XeH Procedure Indications 2.16.840.1.113883.2.51.10.78
|
2022‑06‑17 11:56:56 | DICOM-20150324 | |
| This section contains the reason(s) for the procedure or surgery. This section may include the preprocedure diagnoses as well as symptoms contributing to the reason for the procedure. | ||||
| html | XeH Radiation Exposure and Protection Information 2.16.840.1.113883.2.51.10.81
|
2022‑06‑24 11:24:15 | DICOM-20150324 | |
| Contains information related to the radiation exposure and protection of the patient, as may be required by national or local legal requirements or standards. | ||||
| html | XeH Request 2.16.840.1.113883.2.51.10.62
|
2022‑03‑21 16:04:11 | DICOM-20150324 | |
| Information about the requested imaging studies and associated tests. It may include information on the reason for the request, and on any validation of the request by clinical decision support agains... | ||||
| html | XeH Vital Signs Section 2.16.840.1.113883.2.51.10.82
|
2022‑06‑24 14:17:33 | ||
| The vital signs section contains coded measurement results of a patient’s vital signs. | ||||
| CDA Entry Level Template | ||||
| html | Age Observation 2.16.840.1.113883.10.20.22.4.31
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This Age Observation represents the subject's age at onset of an event or observation. The age of a relative in a Family History Observation at the time of that observation could also be inferred by c... | ||||
| html | Boundary Observation 2.16.840.1.113883.10.20.6.2.11
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| A Boundary Observation contains a list of integer values for the referenced frames of a DICOM multiframe image SOP instance. It identifies the frame numbers within the referenced SOP instance to which... | ||||
| html | Case Identification 1.3.6.1.4.1.19376.1.3.1.1.2
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| Case Identification, when present, SHALL be recorded as an observation under the Notification Organizer as demonstrated. Case Identification SHALL be present when dictated by local case identification... | ||||
| html | CDA Act 2.16.840.1.113883.10.12.301
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Act (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Act SDTC 2.16.840.1.113883.10.12.801
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Act (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Author (Body) 2.16.840.1.113883.10.12.318
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Author (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Author (Body) SDTC 2.16.840.1.113883.10.12.818
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Author (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Clinical Statement 2.16.840.1.113883.10.12.300
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Clinical Statement (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Clinical Statement SDTC 2.16.840.1.113883.10.12.800
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Clinical Statement (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Device 2.16.840.1.113883.10.12.315
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Device (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Device SDTC 2.16.840.1.113883.10.12.815
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Device (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Encounter 2.16.840.1.113883.10.12.302
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Encounter (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Encounter SDTC 2.16.840.1.113883.10.12.802
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Encounter (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA ExternalAct 2.16.840.1.113883.10.12.325
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ExternalAct (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA ExternalAct SDTC 2.16.840.1.113883.10.12.825
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ExternalAct (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA ExternalDocument 2.16.840.1.113883.10.12.328
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ExternalDocument (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA ExternalDocument SDTC 2.16.840.1.113883.10.12.828
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ExternalDocument (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA ExternalObservation 2.16.840.1.113883.10.12.326
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ExternalObservation (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA ExternalObservation SDTC 2.16.840.1.113883.10.12.826
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ExternalObservation (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA ExternalProcedure 2.16.840.1.113883.10.12.327
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ExternalProcedure (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA ExternalProcedure SDTC 2.16.840.1.113883.10.12.827
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ExternalProcedure (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Informant (Body) 2.16.840.1.113883.10.12.319
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Informant Body (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Informant (Body) SDTC 2.16.840.1.113883.10.12.819
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Informant Body (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA LabeledDrug 2.16.840.1.113883.10.12.310
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA LabeledDrug (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA LabeledDrug SDTC 2.16.840.1.113883.10.12.810
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA LabeledDrug (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA ManufacturedProduct 2.16.840.1.113883.10.12.312
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ManufacturedProduct (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA ManufacturedProduct SDTC 2.16.840.1.113883.10.12.812
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ManufacturedProduct (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Material 2.16.840.1.113883.10.12.311
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Material (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Material SDTC 2.16.840.1.113883.10.12.811
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Material (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Observation 2.16.840.1.113883.10.12.303
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Observation (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Observation SDTC 2.16.840.1.113883.10.12.803
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Observation (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA ObservationMedia 2.16.840.1.113883.10.12.304
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ObservationMedia (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA ObservationMedia SDTC 2.16.840.1.113883.10.12.804
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA ObservationMedia (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Organizer 2.16.840.1.113883.10.12.305
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Organizer (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Organizer SDTC 2.16.840.1.113883.10.12.805
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Organizer (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Participant (Body) 2.16.840.1.113883.10.12.321
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Participant (Body) (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Participant (Body) SDTC 2.16.840.1.113883.10.12.821
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Participant (Body) (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Performer (Body) 2.16.840.1.113883.10.12.323
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Performer (Body) (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Performer (Body) SDTC 2.16.840.1.113883.10.12.823
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Performer (Body) (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Place 2.16.840.1.113883.10.12.317
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Place (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA PlayingEntity 2.16.840.1.113883.10.12.313
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA PlayingEntity (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA PlayingEntity SDTC 2.16.840.1.113883.10.12.813
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA PlayingEntity (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Precondition 2.16.840.1.113883.10.12.329
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Precondition (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Precondition SDTC 2.16.840.1.113883.10.12.829
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Precondition (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Procedure 2.16.840.1.113883.10.12.306
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Procedure (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Procedure SDTC 2.16.840.1.113883.10.12.806
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Procedure (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Reference 2.16.840.1.113883.10.12.324
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Reference (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Reference SDTC 2.16.840.1.113883.10.12.824
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Reference (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA RegionOfInterest 2.16.840.1.113883.10.12.307
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA RegionOfInterest (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA RegionOfInterest SDTC 2.16.840.1.113883.10.12.807
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA RegionOfInterest (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA RelatedEntity 2.16.840.1.113883.10.12.316
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA RelatedEntity (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA RelatedEntity SDTC 2.16.840.1.113883.10.12.816
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA RelatedEntity (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Specimen 2.16.840.1.113883.10.12.322
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Specimen (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Specimen SDTC 2.16.840.1.113883.10.12.822
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Specimen (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Subject (Body) 2.16.840.1.113883.10.12.320
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Subject Body (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Subject (Body) SDTC 2.16.840.1.113883.10.12.820
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Subject Body (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA SubstanceAdministration 2.16.840.1.113883.10.12.308
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA SubstanceAdministration (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA SubstanceAdministration SDTC 2.16.840.1.113883.10.12.808
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA SubstanceAdministration (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | CDA Supply 2.16.840.1.113883.10.12.309
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Supply (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | CDA Supply SDTC 2.16.840.1.113883.10.12.809
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template CDA Supply (prototype, directly derived from POCD_RM000040 MIF) + SDTC extensions | ||||
| html | Code Observations 2.16.840.1.113883.10.20.6.2.13
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| DICOM Template 2000 specifies that Imaging Report Elements of Value Type Code are contained in sections. The Imaging Report Elements are inferred from Basic Diagnostic Imaging Report Observations that... | ||||
| html | Drug Monitoring Act 2.16.840.1.113883.10.20.22.4.123
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This template represents the act of monitoring the patient's medication and includes a participation to record the person responsible for monitoring the medication. The prescriber of the medication is... | ||||
| html | Drug Vehicle 2.16.840.1.113883.10.20.22.4.24
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This template represents the vehicle (e.g., saline, dextrose) for administering a medication. | ||||
| html | Human Patient with Non-Human Subject 1.3.6.1.4.1.19376.1.3.3.1.3.1
ref
XDLAB-
|
2009‑12‑04 | 2017 | |
| When the subject of the observations in this part of the report is a sample taken from a non-human subject, such as an animal, a lake, soil or other environmental element, while other parts of the rep... | ||||
| html | IHE Cancer Diagnosis Entry 1.3.6.1.4.1.19376.1.7.3.1.4.14.1
ref
IHE-PCC-
|
2017‑03‑23 08:56:15 | 2016 | |
| A Cancer Diagnosis entry collects details of the patient’s cancer diagnosis, including histology, behavior, primary site, laterality, diagnosis date, TNM Stage, and Best Method of Co... | ||||
| html | IHE Comment Entry 1.3.6.1.4.1.19376.1.5.3.1.4.2
ref
IHE-PCC-
|
2013‑12‑20 | 2014 | |
| This entry allows for a comment to be supplied with each entry. For CDA this structure is usually included in the target act using the <entryRelationship> element defined in the CDA Schema, but can al... | ||||
| html | IHE Coverage Entry 1.3.6.1.4.1.19376.1.5.3.1.4.17
ref
IHE-PCC-
|
2015‑07‑03 17:02:07 | 2014 | |
| Payers shall be recorded as described in CCD: 3.1.2.1.1. | ||||
| html | IHE Payer Entry 1.3.6.1.4.1.19376.1.5.3.1.4.18
ref
IHE-PCC-
|
2016‑10‑14 09:06:18 | 2014 | |
| The payer entry allows information about the patient's sources of payment to be recorded. | ||||
| html | IHE PCC Annotation Comment 2.16.840.1.113883.2.51.10.59
|
2022‑03‑03 11:33:51 | 2017 | |
| ***CANCELLED! USE IHE PCC Comment Entry*** This entry allows for a comment to be supplied with each entry. For CDA this structure is usually included in the target act using the <entryRelationship> e... | ||||
| html | Image Quality 1.2.840.10008.9.15
ref
DICOM-
|
2021‑06‑22 11:06:23 | DICOM-20150324 | |
| Provides a quality assessment for the image set identified by the invoking section. By default unless otherwise identified, applies to the image set interpreted by the document (typically a Study). If... | ||||
| html | Immunization Activity (V3) 2.16.840.1.113883.10.20.22.4.52
ref
ccda-
|
2015‑08‑01 | 2.1 | |
| An Immunization Activity describes immunization substance administrations that have actually occurred or are intended to occur. Immunization Activities in "INT" mood are reflections of immunizations a... | ||||
| html | Immunization Medication Information (V2) 2.16.840.1.113883.10.20.22.4.54
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| The Immunization Medication Information represents product information about the immunization substance. The vaccine manufacturer and vaccine lot number are typically recorded in the medical record an... | ||||
| html | Immunization Refusal Reason 2.16.840.1.113883.10.20.22.4.53
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| The Immunization Refusal Reason documents the rationale for the patient declining an immunization. | ||||
| html | Indication (V2) 2.16.840.1.113883.10.20.22.4.19
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| This template represents the rationale for an action such as an encounter, a medication administration, or a procedure. The id element can be used to reference a problem recorded elsewhere in the docu... | ||||
| html | Instruction (V2) 2.16.840.1.113883.10.20.22.4.20
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| The Instruction template can be used in several ways, such as to record patient instructions within a Medication Activity or to record fill instructions within a supply order. The template's moodCode ... | ||||
| html | IPS Advance Directive Observation 2.16.840.1.113883.10.22.4.37
ref
hl7ips-
|
2020‑05‑08 16:21:54 | TI-2020 | |
| This clinical statement represents Advance Directive Observation findings (e.g., “resuscitation status is Full Code”) rather than orders. It should not be considered a legal document or a substitute f... | ||||
| html | IPS Advance Directive Organizer 2.16.840.1.113883.10.22.4.46
ref
hl7ips-
|
2020‑05‑08 16:11:48 | TI-2020 | |
| This clinical statement groups a set of advance directive observations. | ||||
| html | IPS Allergy and Intolerance Concern 2.16.840.1.113883.10.22.4.5
ref
hl7ips-
|
2016‑11‑11 | STU1 | |
| This template reflects an ongoing concern on behalf of the person that placed the allergy on a patient’s allergy list. A concern may refer to one or more allergies or intolerances. There are different... | ||||
| html | IPS Allergy Certainty Observation 2.16.840.1.113883.10.22.10
ref
hl7ips-
|
2018‑02‑07 12:00:44 | STU1 | |
| This observation represents the certainty associated with a propensity, or potential risk, of a reaction to the identified substance. | ||||
| html | IPS Allergy or Intolerance 2.16.840.1.113883.10.22.4.1
ref
hl7ips-
|
2016‑11‑10 | STU1 | |
| This template reflects a discrete observation about a patient's allergy or intolerance. Because it is a discrete observation, it will have a statusCode of "completed". The eff... | ||||
| html | IPS Allergy Status Observation 2.16.840.1.113883.10.22.4.21
ref
hl7ips-
|
2017‑05‑24 | STU1 | |
| This subordinated observation used by the allergy observation records information about the current status of an allergy or intolerance, for example, whether it is active, in remission, resolved, et c... | ||||
| html | IPS Body Author 2.16.840.1.113883.10.22.4.14
ref
hl7ips-
|
2017‑03‑02 | STU1 | |
| This template represents the Author Participation (including the author timestamp). CDA R2 requires that Author and Author timestamp be asserted in the document header. From there, authorship propagat... | ||||
| html | IPS CDA Device 2.16.840.1.113883.10.22.9.2
ref
hl7ips-
|
2017‑04‑12 | STU1 | |
| This template provides basic information about a device | ||||
| html | IPS Certainty Observation 2.16.840.1.113883.10.22.4.19
ref
hl7ips-
|
2017‑03‑29 | STU1 | |
| This observation represents the verification status to support the clinical status of the condition. | ||||
| html | IPS Comment Activity 2.16.840.1.113883.10.22.4.22
ref
hl7ips-
|
2017‑04‑05 | STU1 | |
| Comments are free text data that cannot otherwise be recorded using data elements already defined by this specification. They are not to be used to record information that can be recorded elsewhere. F... | ||||
| html | IPS Criticality Observation 2.16.840.1.113883.10.22.4.18
ref
hl7ips-
|
2017‑03‑27 | STU1 | |
| This observation represents the gravity of the potential risk for future life-threatening adverse reactions when exposed to a substance known to cause an adverse reaction in that individual. When the ... | ||||
| html | IPS Immunization Medication Information 2.16.840.1.113883.10.22.4.16
ref
hl7ips-
|
2017‑03‑08 | STU1 | |
| The Immunization Medication Information represents product information about the immunization substance. The vaccine manufacturer and vaccine lot number are typically recorded in the medical record an... | ||||
| html | IPS Internal Reference 2.16.840.1.113883.10.22.4.31
ref
hl7ips-
|
2017‑05‑02 | STU1 | |
| This template is used to reference (point to) information contained in other entries within the same document. | ||||
| html | IPS Laboratory Result Observation 2.16.840.1.113883.10.22.4.13
ref
hl7ips-
|
2017‑03‑21 | STU1 | |
| This template constrains the results of a clinical laboratory observation. The result observation includes a statusCode to allow recording the status of an observation. “Pending” results (e.g., a test... | ||||
| html | IPS Manufactured Material 2.16.840.1.113883.10.22.4.3
ref
hl7ips-
|
2021‑08‑02 16:52:27 | 2021 | |
| This entry provides details about the medicinal product. Due to the current absence of global product identifiers the product is described through a set of identifi... | ||||
| html | IPS Medical Device 2.16.840.1.113883.10.22.4.26
ref
hl7ips-
|
2017‑04‑11 | STU1 | |
| The medical devices entry content module describes the kind of device that is, or has been used by the patient | ||||
| html | IPS Medication Information (detail) 2.16.840.1.113883.10.22.4.2
ref
hl7ips-
|
2016‑11‑10 | STU1 | |
| This entry describes the consumable subject of the medication statement. All the information about the medication is provided in the included IPS Manufactured Material template. | ||||
| html | IPS Medication Statement 2.16.840.1.113883.10.22.4.4
ref
hl7ips-
|
2021‑09‑02 12:17:54 | 2021 | |
| An IPS Medication entry describes a medication statement, that is a substance administration that has actually occurred (e.g., pills ingested or injections given) or are intended to ... | ||||
| html | IPS ObservationMedia 2.16.840.1.113883.10.22.4.23
ref
hl7ips-
|
2021‑09‑02 12:02:16 | 2021 | |
| Template CDA ObservationMedia for IPS (prototype, directly derived from POCD_RM000040 MIF) This element is intended to carry a small multimedia content, like an image or a graph to be rendered in the ... | ||||
| html | IPS Pathology Result Observation 2.16.840.1.113883.10.22.4.11
ref
hl7ips-
|
2017‑03‑21 | STU1 | |
| This template constrains the results of an anatomic pathology observation. The result observation includes a statusCode to allow recording the status of an observation. “Pending” results (e.g., a tes... | ||||
| html | IPS Planned Act 2.16.840.1.113883.10.22.4.39
ref
hl7ips-
|
2022‑07‑15 13:55:11 | 2022 | |
| This template represents a Planned Act. It may be a wrapper for intervention-type activities considered to be parts of the same intervention; or it could be used to describe planned acts not rep... | ||||
| html | IPS Planned Encounter 2.16.840.1.113883.10.22.4.40
ref
hl7ips-
|
2020‑05‑08 18:18:38 | TI-2020 | |
| An Encounter is an interaction between a patient and care provider(s) for the purpose of providing healthcare-related service(s). Healthcare services include health assessment. Examp... | ||||
| html | IPS Planned Immunization 2.16.840.1.113883.10.22.4.47
ref
hl7ips-
|
2020‑05‑08 17:29:18 | TI-2020 | |
| A Planned Immunization entry describes the intent of administrating immunization substance. | ||||
| html | IPS Planned Observation 2.16.840.1.113883.10.22.4.41
ref
hl7ips-
|
2020‑05‑08 18:34:42 | TI-2020 | |
| The observation request entry is used to record goals, plans or intention for an observation to be performed (e.g., assessment, laboratory test, imaging study, et cetera). | ||||
| html | IPS Planned Procedure 2.16.840.1.113883.10.22.4.38
ref
hl7ips-
|
2020‑05‑08 17:38:48 | TI-2020 | |
| The procedure entry is used to record procedures which are planned for in the future. | ||||
| html | IPS Pregnancy Expected Delivery Date Observation 2.16.840.1.113883.10.22.4.29
ref
hl7ips-
|
2017‑04‑13 | STU1 | |
| This observation records the Pregnancy Expected Delivery Date for pregnant patients, expressed as a time stamp. The code reflects the method (operationalisation) of how the date was ... | ||||
| html | IPS Pregnancy Observation 2.16.840.1.113883.10.22.4.36
ref
hl7ips-
|
2020‑05‑07 18:36:37 | TI-2020 | |
| A pregnancy observation is a Simple Observation that uses a specific vocabulary to record observations about a patient's current or historical pregnancies. | ||||
| html | IPS Pregnancy Outcome Observation 2.16.840.1.113883.10.22.4.28
ref
hl7ips-
|
2017‑04‑13 | STU1 | |
| A pregnancy outcome observation records a summary over all pregnancies. | ||||
| html | IPS Pregnancy Status Observation 2.16.840.1.113883.10.22.4.27
ref
hl7ips-
|
2020‑07‑14 16:31:53 | 2021 | |
| A pregnancy status observation records whether the patient is currently pregnant or not. If pregnant, an Expected Delivery Date may be specified as an subordinate observation. | ||||
| html | IPS Problem Concern Entry 2.16.840.1.113883.10.22.4.7
ref
hl7ips-
|
2021‑08‑04 08:49:27 | 2021 | |
| This template reflects an ongoing concern on behalf of the provider that placed the concern on a patient’s problem list. The purpose of the concern act is that of supporting the tra... | ||||
| html | IPS Problem Entry 2.16.840.1.113883.10.22.4.8
ref
hl7ips-
|
2021‑08‑04 08:52:52 | 2021 | |
| This template reflects a discrete observation about a patient's problem. Because it is a discrete observation, it will have a statusCode of "completed". The effectiveTime, also refer... | ||||
 IPS Problem Status Observation 2.16.840.1.113883.10.22.4.20
|
Multiple (2) | |||
| This subordinated observation used by the problem observation records information about the current status of a condition, for example, whether it is active, in remission, resolved, et cetera. | ||||
| html | IPS Problem Status Observation 2.16.840.1.113883.10.22.4.20
ref
hl7ips-
|
2021‑09‑02 11:41:28 | 2021 | |
| html | IPS Problem Status Observation 2.16.840.1.113883.10.22.4.20
ref
hl7ips-
|
2017‑03‑29 | STU1 | |
| html | IPS Procedure Entry 2.16.840.1.113883.10.22.4.17
ref
hl7ips-
|
2020‑07‑14 16:35:58 | 2021 | |
| The procedure entry is used to record procedures that have occurred, or which are planned for in the future. | ||||
| html | IPS Radiology Result Observation 2.16.840.1.113883.10.22.4.12
ref
hl7ips-
|
2017‑03‑21 | STU1 | |
| This template represents an observation produced as one of the results of a radiology or other imaging study performed on a patient. In most cases, in the context of a patient summary this observatio... | ||||
| html | IPS Reaction Manifestation 2.16.840.1.113883.10.22.4.6
ref
hl7ips-
|
2016‑11‑15 | STU1 | |
| This clinical statement represents the response to an undesired symptom, finding, etc. due to administered or exposed substance. This reaction may be an undesired symptom, finding, etc. or it could be... | ||||
| html | IPS Result Observation 2.16.840.1.113883.10.22.4.10
ref
hl7ips-
|
2017‑03‑02 | STU1 | |
| This generic template is the basic set of constraints, which apply to any kind of observation grouped in a Result Organizer. The IPS Result Observation template is generic. It is further specialized b... | ||||
| html | IPS Result Organizer 2.16.840.1.113883.10.22.4.9
ref
hl7ips-
|
2017‑03‑02 | STU1 | |
| This template provides a mechanism for grouping result observations. It contains information applicable to all of the contained result observations. The Result Organizer code categorizes the contained... | ||||
| html | IPS Severity Observation 2.16.840.1.113883.10.22.4.25
ref
hl7ips-
|
2017‑04‑07 | STU1 | |
| This clinical statement represents the subjective assessment of the severity of the condition as evaluated by the clinician. The Severity Observation can be associated with a Reactio... | ||||
| html | IPS Social History Alcohol Use 2.16.840.1.113883.10.22.4.35
ref
hl7ips-
|
2017‑06‑29 | STU1 | |
| This template is a specialization of the Social History Observation that may be used to represent alcohol consumption habits. | ||||
| html | IPS Social History Observation 2.16.840.1.113883.10.22.4.48
ref
hl7ips-
|
2020‑05‑10 15:16:16 | TI-2020 | |
| This template represents a patient's occupations, lifestyle, and environmental health risk factors. Demographic data (e.g., marital status, race, ethnicity, religious affiliation) are captured in the ... | ||||
| html | IPS Social History Tobacco Use 2.16.840.1.113883.10.22.4.34
ref
hl7ips-
|
2017‑06‑20 | STU1 | |
| This template is a specialization of the Social History Observation that may be used to represent smoking or tobacco habits. | ||||
| html | IPS Specimen Collection 2.16.840.1.113883.10.22.4.30
ref
hl7ips-
|
2017‑04‑14 | STU1 | |
| Specimen Collection is used when a set of laboratory or pathology observations produced on one or more specimens need to be associated with the minimal characteristics of the specimen(s): specimen so... | ||||
| html | IPS Survey Observation 2.16.840.1.113883.10.22.4.43
ref
hl7ips-
|
2020‑05‑08 19:05:11 | TI-2020 | |
| Survey observations are used to record responses to assessment instruments. They are simple observations conforming to the CCD Result template. The vocabulary and data type constrain... | ||||
| html | IPS Survey Panel 2.16.840.1.113883.10.22.4.42
ref
hl7ips-
|
2020‑05‑08 19:02:26 | TI-2020 | |
| A survey panel collects related survey observations. | ||||
| html | Laboratory Battery Organizer 1.3.6.1.4.1.19376.1.3.1.4
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| A Laboratory Battery Organizer is used to group Laboratory Observations (1.3.6.1.4.1.19376.1.3.1.6) for a battery of tests. Laboratory Battery Organizer, when present, SHALL be recorded as an organize... | ||||
| html | Laboratory Isolate Organizer 1.3.6.1.4.1.19376.1.3.1.5
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| The Laboratory Isolate Organizer SHALL be used only if the entry represents a microbiology specimen study with isolates discovered on the specimen. The isolate is represented by the Isolate role playe... | ||||
| html | Laboratory Observation 1.3.6.1.4.1.19376.1.3.1.6
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| The document SHALL contain at least one Laboratory Observation (See REFERENCE) under the Specimen Act of each Laboratory Data Processing Entry (See REFERENCE). The Laboratory Observation SHALL record ... | ||||
| html | Laboratory Report Data Processing Entry 1.3.6.1.4.1.19376.1.3.1
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| One Laboratory Report Data Processing Entry SHALL be present in each leaf section of the report. The entry element SHALL be present and have its root attribute valued "1.3.6.1.4.1.19376.1.3.1". The en... | ||||
| html | Medication Activity (V2) 2.16.840.1.113883.10.20.22.4.16
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| A Medication Activity describes substance administrations that have actually occurred (e.g., pills ingested or injections given) or are intended to occur (e.g., "take 2 tablets twice a day for the nex... | ||||
| html | Medication Dispense (V2) 2.16.840.1.113883.10.20.22.4.18
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| This template records the act of supplying medications (i.e., dispensing). | ||||
| html | Medication Free Text Sig 2.16.840.1.113883.10.20.22.4.147
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| The template is available to explicitly identify the free text Sig within each medication. An example free text sig: Thyroxin 150 ug, take one tab by mouth every morning. | ||||
| html | Medication Information (V2) 2.16.840.1.113883.10.20.22.4.23
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| A medication should be recorded as a pre-coordinated ingredient + strength + dose form (e.g., “metoprolol 25mg tablet”, “amoxicillin 400mg/5mL suspension”) where possible. This includes RxNorm codes w... | ||||
| html | Medication Supply Order (V2) 2.16.840.1.113883.10.20.22.4.17
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| This template records the intent to supply a patient with medications. | ||||
| html | Multimedia Embedded Content 1.3.6.1.4.1.19376.1.3.10.9.2
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| The embedding of multimedia content (e.g. a small image of an electrophoresis chart) in a Laboratory Report is consistent with the CDA R2 Standard. The CDA schema allows both embedded multimedia objec... | ||||
| html | Non-Human Subject 1.3.6.1.4.1.19376.1.3.3.1.2.1
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| When the subject of the observations in the report is a sample exclusively taken from a non-human subject, such as an animal, a lake, soil or other environmental element, the following SHALL be presen... | ||||
| html | Notifiable Condition 1.3.6.1.4.1.19376.1.3.1.1.1
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| Notifiable Condition, when present, SHALL be recorded as an <observation> under the Notification Organizer as demonstrated. Notifiable Condition SHALL be present when dictated by local public health r... | ||||
| html | Notification Organizer 1.3.6.1.4.1.19376.1.3.1.1
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| The document MAY contain a Notification Organizer in an <entryRelationship> under the Specimen Act of a Laboratory Data Processing Entry as demonstrated in the figure below. This <organizer> SHALL be ... | ||||
| html | Observation Media Entry 1.3.6.1.4.1.19376.1.4.1.4.7
ref
DICOM-
|
2021‑06‑21 16:51:49 | DICOM-20150324 | |
| The observationMedia Entry provides an in-line graphic depiction of the section findings. It is referenced by a renderMultiMedia element in the section text. Typical uses are for graphic representatio... | ||||
| html | Outbreak Identification 1.3.6.1.4.1.19376.1.3.1.1.3
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| Outbreak Identification, when present, SHALL be recorded as an observation under the Notification Organizer as demonstrated. Outbreak Identification SHALL be present when dictated by local outbreak id... | ||||
| html | Precondition for Substance Administration (V2) 2.16.840.1.113883.10.20.22.4.25
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| A criterion for administration can be used to record that the medication is to be administered only when the associated criteria are met. | ||||
| html | Priority Preference 2.16.840.1.113883.10.20.22.4.143
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This template represents priority preferences chosen by a patient or a care provider. Priority preferences are choices made by care providers or patients or both relative to options for care or treatm... | ||||
| html | Problem Observation (V3) 2.16.840.1.113883.10.20.22.4.4
ref
ccda-
|
2015‑08‑01 | 2.1 | |
| This template reflects a discrete observation about a patient's problem. Because it is a discrete observation, it will have a statusCode of "completed". The effectiveTime, also referred to as the “bio... | ||||
| html | Problem Status 2.16.840.1.113883.10.20.22.4.6
ref
ccda-
|
2014‑06‑09 | 2.1-OLD | |
| The Problem Status records whether the indicated problem is active, inactive, or resolved. | ||||
| html | Procedural Medication 1.2.840.10008.9.13
ref
DICOM-
|
2021‑06‑22 10:02:08 | DICOM-20150324 | |
| Procedural medication describes a substance administration that has actually occurred prior to or during a procedure (e.g., imaging contrast/agents, anti-histamines, anti-anxiety, be... | ||||
| html | Procedure Activity Procedure (V2) 2.16.840.1.113883.10.20.22.4.14
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| The common notion of "procedure" is broader than that specified by the HL7 Version 3 Reference Information Model (RIM). Therefore procedure templates can be represented with various RIM classes: act (... | ||||
| html | Procedure Technique 1.2.840.10008.9.14
ref
DICOM-
|
2021‑06‑22 09:43:16 | DICOM-20150324 | |
| The Procedure Technique entry allows the encoding of various parameters of the image acquisition. Other details may be found in other entries (e.g., procedural medication). | ||||
| html | Product Instance 2.16.840.1.113883.10.20.22.4.37
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This clinical statement represents a particular device that was placed in a patient or used as part of a procedure or other act. This provides a record of the identifier and other details about the gi... | ||||
| html | Prognosis Observation 2.16.840.1.113883.10.20.22.4.113
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This template represents the patient’s prognosis, which must be associated with a problem observation. It may serve as an alert to scope intervention plans. The effectiveTime represents the clinically... | ||||
| html | Purpose of Reference Observation 2.16.840.1.113883.10.20.6.2.9
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| A Purpose of Reference Observation describes the purpose of the DICOM composite object reference. Appropriate codes, such as externally defined DICOM codes, may be used to specify the semantics of the... | ||||
| html | Quantity Measurement Observation 2.16.840.1.113883.10.20.6.2.14
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| A Quantity Measurement Observation records quantity measurements based on image data such as linear, area, volume, and numeric measurements. The codes in DIRQuantityMeasurementTypeCodes (ValueSet: 2.1... | ||||
| html | Reaction Observation (V2) 2.16.840.1.113883.10.20.22.4.9
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| This clinical statement represents the response to an undesired symptom, finding, etc. due to administered or exposed substance. A reaction can be defined described with respect to i... | ||||
| html | Referenced Frames Observation 2.16.840.1.113883.10.20.6.2.10
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| A Referenced Frames Observation is used if the referenced DICOM SOP instance is a multiframe image and the reference does not apply to all frames. The list of integer values for the referenced frames ... | ||||
| html | Series Act 2.16.840.1.113883.10.20.22.4.63
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| A Series Act contains the DICOM series information for referenced DICOM composite objects. The series information defines the attributes that are used to group composite instances into distinct logica... | ||||
| html | Service Delivery Location 2.16.840.1.113883.10.20.22.4.32
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This clinical statement represents the location of a service event where an act, observation or procedure took place. | ||||
| html | Severity Observation (V2) 2.16.840.1.113883.10.20.22.4.8
ref
ccda-
|
2014‑06‑09 | 2.1 | |
| This clinical statement represents the gravity of the reaction. The Severity Observation characterizes the Reaction Observation. A person may manifest many symptoms in a reaction to ... | ||||
| html | SOP Instance Observation 1.2.840.10008.9.18
ref
DICOM-
|
2021‑06‑22 09:07:17 | DICOM-20150324 | |
| A SOP Instance Observation contains the DICOM Service Object Pair (SOP) Instance information for referenced DICOM composite objects. The SOP Instance act class is used to reference b... | ||||
| html | SOP Instance Observation 2.16.840.1.113883.10.20.6.2.8
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| A SOP Instance Observation contains the DICOM Service Object Pair (SOP) Instance information for referenced DICOM composite objects. The SOP Instance act class is used to reference both image and non-... | ||||
| html | Specimen Collection 1.3.6.1.4.1.19376.1.3.1.2
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| Specimen Collection, when present, SHALL be recorded under the Specimen Act in an entryRelationship under the Laboratory Data Processing Entry. The table below shows how the information for this eleme... | ||||
| html | Specimen Received 1.3.6.1.4.1.19376.1.3.1.3
ref
XDLAB-
|
2008‑08‑08 | 2017 | |
| Specimen Received, when present, SHALL be recorded under the Specimen Act in an entryRelationship under the Laboratory Data Processing Entry. The table below shows how the information for this element... | ||||
| html | Study Act 2.16.840.1.113883.10.20.6.2.6
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| A Study Act contains the DICOM study information that defines the characteristics of a referenced medical study performed on a patient. A study is a collection of one or more series of medical images,... | ||||
| html | Substance Administered Act 2.16.840.1.113883.10.20.22.4.118
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This template represents the administration course in a series. The entryRelationship/sequenceNumber in the containing template shows the order of this particular administration in that medication ser... | ||||
| html | UV Subordinate Substance Administration 2.16.840.1.113883.10.21.4.6
ref
pharmcda-
|
2017‑04‑30 | ||
| Universal Subordinate Substance Administration to convey information about dosages | ||||
| html | UV Use Period 2.16.840.1.113883.10.21.9.1
ref
pharmcda-
|
2017‑05‑02 | ||
| This element encodes the start and stop time of the medication regimen. This is an interval of time (xsi:type='IVL_TS'), and must be specified as shown. This is an additional constraint placed upon C... | ||||
| html | XeH Admission / Discharge Diagnosis 2.16.840.1.113883.2.51.10.27
|
2021‑10‑01 08:20:28 | ||
| This template reflects a discrete observation about a patient's problem. Because it is a discrete observation, it will have a statusCode of "completed". The effectiveTime, also refer... | ||||
| html | XeH Age Observation 2.16.840.1.113883.2.51.10.21
|
2021‑09‑22 17:23:50 | 0.1 | |
| This Age Observation represents the subject's age at onset of an event or observation. The age of a relative in a Family History Observation at the time of that observation could also be inferred by c... | ||||
| html | XeH Care Provision Act 2.16.840.1.113883.2.51.10.38
|
2021‑10‑18 16:17:01 | ||
| Template CDA Act (prototype, directly derived from POCD_RM000040 MIF) | ||||
| html | XeH Care Team Act 2.16.840.1.113883.2.51.10.37
|
2021‑10‑18 16:15:10 | ||
| This template describes the care provision act performed by a care team (reference center and practitioner). | ||||
| html | XeH Encounter 2.16.840.1.113883.2.51.10.46
|
2021‑11‑18 12:15:51 | ||
| Generic XeHealth CDA Encounter template + SDTC extensions | ||||
| html | XeH Family History Death Observation 2.16.840.1.113883.2.51.10.22
|
2021‑09‑22 17:24:49 | 0.1 | |
| This clinical statement records whether the family member is deceased. | ||||
| html | XeH Family History Observation 2.16.840.1.113883.2.51.10.20
|
2021‑09‑22 17:22:16 | 0.1 | |
| Family History Observations related to a particular family member are contained within a Family History Organizer. The effectiveTime in the Family History Observation is the biologically or clinically... | ||||
| html | XeH Family History Organizer 2.16.840.1.113883.2.51.10.19
|
2021‑09‑21 17:45:23 | 0.1 | |
| The Family History Organizer associates a set of observations with a family member. For example, the Family History Organizer can group a set of observations about the patient’s father. | ||||
| html | XeH Immunization 2.16.840.1.113883.2.51.10.64
|
2022‑05‑06 09:23:08 | ||
| An Immunization entry describes immunization substance administrations that have actually occurred. | ||||
| html | XeH Immunization Refusal Reason 2.16.840.1.113883.2.51.10.66
|
2022‑05‑06 09:42:03 | ||
| The Immunization Refusal Reason documents the rationale for the patient declining an immunization. | ||||
| html | XeH Internal Reference 2.16.840.1.113883.2.51.10.18
|
2021‑09‑21 17:43:00 | 0.1 | |
| This template is used to reference (point to) information contained in other entries within the same document. | ||||
| html | XeH Laboratory Battery Organizer 2.16.840.1.113883.2.51.10.70
|
2022‑05‑09 22:33:51 | 2017 | |
| A Laboratory Battery Organizer is used to group Laboratory Observations (1.3.6.1.4.1.19376.1.3.1.6) for a battery of tests. Laboratory Battery Organizer, when present, SHALL be recorded as an organize... | ||||
| html | XeH Laboratory Observation 2.16.840.1.113883.2.51.10.56
|
2022‑02‑16 15:03:27 | 0.1 | |
| The document SHALL contain at least one Laboratory Observation (See REFERENCE) under the Specimen Act of each Laboratory Data Processing Entry (See REFERENCE). The Laboratory Observation SHALL record ... | ||||
| html | XeH Laboratory Report Data Processing Entry 2.16.840.1.113883.2.51.10.36
|
2021‑10‑07 00:14:07 | 2017 | |
| One Laboratory Report Data Processing Entry SHALL be present in each leaf section of the report. The entry element SHALL be present and have its root attribute valued "1.3.6.1.4.1.19376.1.3.1". The en... | ||||
| html | XeH Medication Statement 2.16.840.1.113883.2.51.10.40
|
2021‑10‑19 11:09:33 | ||
| An IPS Medication entry describes a medication statement, that is a substance administration that has actually occurred (e.g., pills ingested or injections given) or are intended to ... | ||||
| html | XeH Notification Organizer 2.16.840.1.113883.2.51.10.43
|
2021‑11‑02 09:58:35 | 0.1 | |
| The document MAY contain a Notification Organizer in an <entryRelationship> under the Specimen Act of a Laboratory Data Processing Entry as demonstrated in the figure below. This <or... | ||||
| html | XeH Patient Contact [body] 2.16.840.1.113883.2.51.10.35
|
2021‑10‑01 17:51:02 | wip | |
| Patient contacts or the Preferred Health Professional to contact in case of emergency. | ||||
| html | XeH Problem Concern Entry 2.16.840.1.113883.2.51.10.24
|
2021‑09‑24 09:38:56 | 0.1 | |
| This template reflects an ongoing concern on behalf of the provider that placed the concern on a patient’s problem list. The purpose of the concern act is that of supporting the tra... | ||||
| html | XeH Problem Entry 2.16.840.1.113883.2.51.10.25
|
2021‑09‑24 09:49:58 | 0.1 | |
| This template reflects a discrete observation about a patient's problem. Because it is a discrete observation, it will have a statusCode of "completed". The effectiveTime, also refer... | ||||
| html | XeH Problem Status Trend 2.16.840.1.113883.2.51.10.32
|
2021‑10‑01 09:36:42 | wip | |
| This subordinated observation used by the problem observation records information about how patient's given disease, condition, or ability is trending. | ||||
| html | XeH Procedure Technique 2.16.840.1.113883.2.51.10.75
|
2022‑06‑10 10:08:20 | DICOM-20150324 | |
| The Procedure Technique entry allows the encoding of various parameters of the image acquisition. Other details may be found in other entries (e.g., procedural medication). | ||||
| html | XeH Prognosis Observation 2.16.840.1.113883.2.51.10.51
|
2021‑12‑17 09:14:28 | ||
| This template represents the patient’s prognosis, which must be associated with a problem observation. It may serve as an alert to scope intervention plans. The effectiveTime represents the clinically... | ||||
| html | XeH Specimen Collection 2.16.840.1.113883.2.51.10.42
|
2021‑10‑22 13:33:46 | 2021 | |
| Specimen Collection, when present, SHALL be recorded under the Specimen Act in an entryRelationship under the Laboratory Data Processing Entry. The table below shows how the information for this eleme... | ||||
| html | XeH Vital Signs Observation 2.16.840.1.113883.2.51.10.68
|
2022‑05‑06 11:36:37 | ||
| A vital signs observation is a simple observation that uses a specific vocabulary, and inherits constraints from CCD. | ||||
| html | XeH Vital Signs Organizer 2.16.840.1.113883.2.51.10.69
|
2022‑05‑06 12:00:45 | ||
| A vital signs organizer collects vital signs observations. | ||||
| HL7 V2/V3 Datatype Level Template | ||||
| html | IPS Address 2.16.840.1.113883.10.22.11
ref
hl7ips-
|
2018‑04‑04 15:41:36 | STU1 | |
| Reusable address template | ||||
| html | US Realm Address (AD.US.FIELDED) 2.16.840.1.113883.10.20.22.5.2
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| Reusable address template, for use in US Realm CDA Header. | ||||
| html | US Realm Person Name (PN.US.FIELDED) 2.16.840.1.113883.10.20.22.5.1.1
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| The US Realm Clinical Document Person Name datatype flavor is a set of reusable constraints that can be used for Persons. | ||||
| Template type not specified | ||||
| html | Author Participation 2.16.840.1.113883.10.20.22.4.119
ref
ccda-
|
2015‑08‑13 | 2.1 | |
| This template represents the Author Participation (including the author timestamp). CDA R2 requires that Author and Author timestamp be asserted in the document header. From there, authorship propagat... | ||||
| html | Author with Name, Addr, Telecom 1.3.6.1.4.1.19376.1.3.10.9.17
ref
XDLAB-
|
2016‑07‑05 | 2017 | |
| General template for multiple use (see ART-DECOR 'Used by Template id' for current usings) | ||||
| html | General Section Entries 1.2.840.10008.9.23
ref
DICOM-
|
2021‑06‑21 17:25:30 | DICOM-20150324 | |
| This template specifies the common set of structured entries that may be included in a CDA imaging report section, and an author participation for the section. | ||||
| html | Laboratory Device 1.3.6.1.4.1.19376.1.3.10.9.19
ref
XDLAB-
|
2016‑07‑05 | 2017 | |
| This module declares a laboratory device (analyzer). It is consistent with the CDA standard regarding participant and requires in addition the name, addr and telecom for all... | ||||
| html | Organization with Name, Addr, Telecom 1.3.6.1.4.1.19376.1.3.10.9.13
ref
XDLAB-
|
2016‑07‑05 | 2017 | |
| General template for multiple use (see ART-DECOR 'Used by Template id' for current usings) | ||||
| html | PlayingEntity or person with Name 1.3.6.1.4.1.19376.1.3.10.9.18
ref
XDLAB-
|
2016‑07‑05 | 2017 | |
| General template for multiple use (see ART-DECOR 'Used by Template id' for current usings) | ||||
| html | SDTC inFulfillmentOf1 2.16.840.1.113883.10.12.901
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template SDTC Prototype for inFulfillmentOf1 from the SDTC.xsd schema | ||||
| html | SDTCpatient 2.16.840.1.113883.10.12.902
ref
ad1bbr-
|
2005‑09‑07 | ||
| Template SDTC Prototype for patient from the SDTC.xsd schema | ||||
| html | Text 1.2.840.10008.9.19
ref
DICOM-
|
2021‑06‑21 15:03:03 | DICOM-20150324 | |
| This template specifies the common set of narrative block markup that may be included in a CDA imaging report section | ||||
| html | Text2 2.16.840.1.113883.2.51.10.3
|
2021‑06‑22 15:24:21 | DICOM-20150324 | |
| html | XeH General Section Entries 2.16.840.1.113883.2.51.10.76
|
2022‑06‑17 11:12:40 | DICOM-20150324 | |
| This template specifies the common set of structured entries that may be included in a CDA imaging report section, and an author participation for the section. | ||||
| html | XeH Text 2.16.840.1.113883.2.51.10.60
|
2022‑03‑17 11:46:57 | DICOM-20150324 | |
| This template specifies the common set of narrative block markup that may be included in a CDA imaging report section | ||||
Template Summary
| Templates | 346 | |
Templates per Scenario
Item Labels per Template
| Label | Template id | Template name | Link | as of | |
|---|---|---|---|---|---|
| 6.3.3.2.2 |  |
2.16.840.1.113883.2.51.10.83 | XeH Hospital Course Section | 2.16.840.1.113883.2.51.10.83 | 2022‑06‑24 15:29:00 |
| 6.3.3.7.1 | |
1.3.6.1.4.1.19376.1.5.3.1.1.5.3.7 | IHE Payers section | 1.3.6.1.4.1.19376.1.5.3.1.1.5.3.7 | 2015‑07‑02 21:32:44 |
| 6.3.4.36 | |
1.3.6.1.4.1.19376.1.5.3.1.4.17 | IHE Coverage Entry | 1.3.6.1.4.1.19376.1.5.3.1.4.17 | 2015‑07‑03 17:02:07 |
| 6.3.4.37 | |
1.3.6.1.4.1.19376.1.5.3.1.4.18 | IHE Payer Entry | 1.3.6.1.4.1.19376.1.5.3.1.4.18 | 2016‑10‑14 09:06:18 |
| 6.3.4.56 | |
1.3.6.1.4.1.19376.1.7.3.1.4.14.1 | IHE Cancer Diagnosis Entry | 1.3.6.1.4.1.19376.1.7.3.1.4.14.1 | 2017‑03‑23 08:56:15 |
| CONF:1098‑10375 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑10499 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑10502 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑10503 | |
2.16.840.1.113883.10.20.22.4.20 | Instruction (V2) | 2.16.840.1.113883.10.20.22.4.20 | 2014‑06‑09 |
| CONF:1098‑10504 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑10505 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑10506 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑10507 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑10517 | |
2.16.840.1.113883.10.20.22.4.25 | Precondition for Substance Administration (V2) | 2.16.840.1.113883.10.20.22.4.25 | 2014‑06‑09 |
| CONF:1098‑10521 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑10523 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑10525 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1098‑15143 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑15144 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑16851 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑16884 | |
2.16.840.1.113883.10.20.22.4.20 | Instruction (V2) | 2.16.840.1.113883.10.20.22.4.20 | 2014‑06‑09 |
| CONF:1098‑19168 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1098‑19203 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑19204 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑19205 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑28656 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28657 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28658 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28660 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28661 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28662 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28663 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28664 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28665 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28667 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑28668 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑29035 | |
2.16.840.1.113883.10.20.22.4.113 | Prognosis Observation | 2.16.840.1.113883.10.20.22.4.113 | 2015‑08‑13 |
| CONF:1098‑29036 | |
2.16.840.1.113883.10.20.22.4.113 | Prognosis Observation | 2.16.840.1.113883.10.20.22.4.113 | 2015‑08‑13 |
| CONF:1098‑29037 | |
2.16.840.1.113883.10.20.22.4.113 | Prognosis Observation | 2.16.840.1.113883.10.20.22.4.113 | 2015‑08‑13 |
| CONF:1098‑29038 | |
2.16.840.1.113883.10.20.22.4.113 | Prognosis Observation | 2.16.840.1.113883.10.20.22.4.113 | 2015‑08‑13 |
| CONF:1098‑29039 | |
2.16.840.1.113883.10.20.22.4.113 | Prognosis Observation | 2.16.840.1.113883.10.20.22.4.113 | 2015‑08‑13 |
| CONF:1098‑29469 | |
2.16.840.1.113883.10.20.22.4.113 | Prognosis Observation | 2.16.840.1.113883.10.20.22.4.113 | 2015‑08‑13 |
| CONF:1098‑30820 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑30821 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑30823 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑30949 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑30950 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑30951 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑30952 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑30953 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑30954 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑30957 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑30958 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑31123 | |
2.16.840.1.113883.10.20.22.4.113 | Prognosis Observation | 2.16.840.1.113883.10.20.22.4.113 | 2015‑08‑13 |
| CONF:1098‑31150 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑31229 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑31350 | |
2.16.840.1.113883.10.20.22.4.113 | Prognosis Observation | 2.16.840.1.113883.10.20.22.4.113 | 2015‑08‑13 |
| CONF:1098‑31471 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31472 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31473 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31474 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31475 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31476 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31478 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31479 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31480 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31481 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31500 | |
2.16.840.1.113883.10.20.22.4.118 | Substance Administered Act | 2.16.840.1.113883.10.20.22.4.118 | 2015‑08‑13 |
| CONF:1098‑31501 | |
2.16.840.1.113883.10.20.22.4.118 | Substance Administered Act | 2.16.840.1.113883.10.20.22.4.118 | 2015‑08‑13 |
| CONF:1098‑31502 | |
2.16.840.1.113883.10.20.22.4.118 | Substance Administered Act | 2.16.840.1.113883.10.20.22.4.118 | 2015‑08‑13 |
| CONF:1098‑31503 | |
2.16.840.1.113883.10.20.22.4.118 | Substance Administered Act | 2.16.840.1.113883.10.20.22.4.118 | 2015‑08‑13 |
| CONF:1098‑31504 | |
2.16.840.1.113883.10.20.22.4.118 | Substance Administered Act | 2.16.840.1.113883.10.20.22.4.118 | 2015‑08‑13 |
| CONF:1098‑31505 | |
2.16.840.1.113883.10.20.22.4.118 | Substance Administered Act | 2.16.840.1.113883.10.20.22.4.118 | 2015‑08‑13 |
| CONF:1098‑31506 | |
2.16.840.1.113883.10.20.22.4.118 | Substance Administered Act | 2.16.840.1.113883.10.20.22.4.118 | 2015‑08‑13 |
| CONF:1098‑31509 | |
2.16.840.1.113883.10.20.22.4.118 | Substance Administered Act | 2.16.840.1.113883.10.20.22.4.118 | 2015‑08‑13 |
| CONF:1098‑31515 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑31516 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑31517 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑31518 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑31520 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑31543 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑31671 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑31881 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑31882 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑31884 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑31920 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑31921 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑31922 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑32017 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑32018 | |
2.16.840.1.113883.10.20.22.4.119 | Author Participation | 2.16.840.1.113883.10.20.22.4.119 | 2015‑08‑13 |
| CONF:1098‑32327 | |
2.16.840.1.113883.10.20.22.4.143 | Priority Preference | 2.16.840.1.113883.10.20.22.4.143 | 2015‑08‑13 |
| CONF:1098‑32358 | |
2.16.840.1.113883.10.20.22.4.123 | Drug Monitoring Act | 2.16.840.1.113883.10.20.22.4.123 | 2015‑08‑13 |
| CONF:1098‑32360 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑32362 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑32396 | |
2.16.840.1.113883.10.20.22.4.25 | Precondition for Substance Administration (V2) | 2.16.840.1.113883.10.20.22.4.25 | 2014‑06‑09 |
| CONF:1098‑32473 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑32474 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑32479 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑32498 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑32504 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑32506 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑32570 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑32577 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1098‑32578 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑32579 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑32580 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑32598 | |
2.16.840.1.113883.10.20.22.4.20 | Instruction (V2) | 2.16.840.1.113883.10.20.22.4.20 | 2014‑06‑09 |
| CONF:1098‑32602 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑32603 | |
2.16.840.1.113883.10.20.22.4.25 | Precondition for Substance Administration (V2) | 2.16.840.1.113883.10.20.22.4.25 | 2014‑06‑09 |
| CONF:1098‑32775 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑32776 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑32777 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑32907 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑32908 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑32950 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7323 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7325 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7326 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7328 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7329 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7332 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7333 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7334 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7335 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7337 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7338 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7340 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7341 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7343 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7344 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7345 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1098‑7346 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1098‑7347 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1098‑7352 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1098‑7356 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1098‑7369 | |
2.16.840.1.113883.10.20.22.4.25 | Precondition for Substance Administration (V2) | 2.16.840.1.113883.10.20.22.4.25 | 2014‑06‑09 |
| CONF:1098‑7372 | |
2.16.840.1.113883.10.20.22.4.25 | Precondition for Substance Administration (V2) | 2.16.840.1.113883.10.20.22.4.25 | 2014‑06‑09 |
| CONF:1098‑7391 | |
2.16.840.1.113883.10.20.22.4.20 | Instruction (V2) | 2.16.840.1.113883.10.20.22.4.20 | 2014‑06‑09 |
| CONF:1098‑7392 | |
2.16.840.1.113883.10.20.22.4.20 | Instruction (V2) | 2.16.840.1.113883.10.20.22.4.20 | 2014‑06‑09 |
| CONF:1098‑7393 | |
2.16.840.1.113883.10.20.22.4.20 | Instruction (V2) | 2.16.840.1.113883.10.20.22.4.20 | 2014‑06‑09 |
| CONF:1098‑7396 | |
2.16.840.1.113883.10.20.22.4.20 | Instruction (V2) | 2.16.840.1.113883.10.20.22.4.20 | 2014‑06‑09 |
| CONF:1098‑7408 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑7409 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑7410 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑7411 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑7412 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑7416 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1098‑7427 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7428 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7429 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7430 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7432 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7434 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7436 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7438 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7439 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7442 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7444 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7445 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1098‑7451 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7452 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7453 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7454 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7455 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7456 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7457 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7458 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7459 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7461 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7467 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7468 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7473 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7474 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑7480 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑7481 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑7482 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑7483 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑7487 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑7488 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑7489 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1098‑7496 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7497 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7499 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7500 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7506 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7507 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7508 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7513 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7514 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7515 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7516 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7517 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7518 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7519 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7520 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7522 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7523 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7524 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7525 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7526 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7536 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7537 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7539 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7540 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7542 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7543 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7544 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7547 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7549 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7552 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7553 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7555 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1098‑7580 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7581 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1098‑7652 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7653 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7654 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7655 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7656 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7661 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7662 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7668 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7670 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7683 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7697 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7704 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7716 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7718 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7720 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7722 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7731 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7732 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7733 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7734 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7735 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7736 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7737 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7751 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7752 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7765 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7766 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7768 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7769 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7770 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7771 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7772 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7773 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7775 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7776 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7777 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7779 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7780 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7886 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑7887 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑8009 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1098‑9002 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑9004 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑9005 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑9006 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑9007 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑9012 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑9014 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1098‑9331 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1098‑9334 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1198‑10042 | |
2.16.840.1.113883.2.51.10.2 | XeH Diagnostic Imaging Report | 2.16.840.1.113883.2.51.10.2 | 2021‑06‑21 14:23:14 |
| CONF:1198‑10139 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑10384 | |
2.16.840.1.113883.10.20.22.2.37 | Complications Section (V3) | 2.16.840.1.113883.10.20.22.2.37 | 2015‑08‑01 |
| CONF:1198‑10498 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑14833 | |
2.16.840.1.113883.2.51.10.2 | XeH Diagnostic Imaging Report | 2.16.840.1.113883.2.51.10.2 | 2021‑06‑21 14:23:14 |
| CONF:1198‑14907 | |
2.16.840.1.113883.2.51.10.2 | XeH Diagnostic Imaging Report | 2.16.840.1.113883.2.51.10.2 | 2021‑06‑21 14:23:14 |
| CONF:1198‑14926 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑14927 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑15453 | |
2.16.840.1.113883.10.20.22.2.37 | Complications Section (V3) | 2.16.840.1.113883.10.20.22.2.37 | 2015‑08‑01 |
| CONF:1198‑15603 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑15604 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑16749 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑16750 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑29951 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑30695 | |
2.16.840.1.113883.2.51.10.2 | XeH Diagnostic Imaging Report | 2.16.840.1.113883.2.51.10.2 | 2021‑06‑21 14:23:14 |
| CONF:1198‑30932 | |
2.16.840.1.113883.2.51.10.2 | XeH Diagnostic Imaging Report | 2.16.840.1.113883.2.51.10.2 | 2021‑06‑21 14:23:14 |
| CONF:1198‑30933 | |
2.16.840.1.113883.2.51.10.2 | XeH Diagnostic Imaging Report | 2.16.840.1.113883.2.51.10.2 | 2021‑06‑21 14:23:14 |
| CONF:1198‑31063 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑31147 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑31151 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑31510 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑31511 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑31512 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑31513 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑31531 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑31532 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑31870 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑31871 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑32359 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑32508 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑32515 | |
2.16.840.1.113883.2.51.10.2 | XeH Diagnostic Imaging Report | 2.16.840.1.113883.2.51.10.2 | 2021‑06‑21 14:23:14 |
| CONF:1198‑32528 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑32538 | |
2.16.840.1.113883.10.20.22.2.37 | Complications Section (V3) | 2.16.840.1.113883.10.20.22.2.37 | 2015‑08‑01 |
| CONF:1198‑32753 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32754 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32755 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32756 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32770 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32771 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32772 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32775 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32776 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32777 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32778 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32779 | |
2.16.840.1.113883.10.20.22.4.147 | Medication Free Text Sig | 2.16.840.1.113883.10.20.22.4.147 | 2015‑08‑13 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.2.37 | Complications Section (V3) | 2.16.840.1.113883.10.20.22.2.37 | 2015‑08‑01 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.14 | Procedure Activity Procedure (V2) | 2.16.840.1.113883.10.20.22.4.14 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.16 | Medication Activity (V2) | 2.16.840.1.113883.10.20.22.4.16 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.17 | Medication Supply Order (V2) | 2.16.840.1.113883.10.20.22.4.17 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.18 | Medication Dispense (V2) | 2.16.840.1.113883.10.20.22.4.18 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.19 | Indication (V2) | 2.16.840.1.113883.10.20.22.4.19 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.20 | Instruction (V2) | 2.16.840.1.113883.10.20.22.4.20 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.23 | Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.23 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.25 | Precondition for Substance Administration (V2) | 2.16.840.1.113883.10.20.22.4.25 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.54 | Immunization Medication Information (V2) | 2.16.840.1.113883.10.20.22.4.54 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.8 | Severity Observation (V2) | 2.16.840.1.113883.10.20.22.4.8 | 2014‑06‑09 |
| CONF:1198‑32936 | |
2.16.840.1.113883.10.20.22.4.9 | Reaction Observation (V2) | 2.16.840.1.113883.10.20.22.4.9 | 2014‑06‑09 |
| CONF:1198‑32960 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8174 | |
2.16.840.1.113883.10.20.22.2.37 | Complications Section (V3) | 2.16.840.1.113883.10.20.22.2.37 | 2015‑08‑01 |
| CONF:1198‑8176 | |
2.16.840.1.113883.10.20.22.2.37 | Complications Section (V3) | 2.16.840.1.113883.10.20.22.2.37 | 2015‑08‑01 |
| CONF:1198‑8177 | |
2.16.840.1.113883.10.20.22.2.37 | Complications Section (V3) | 2.16.840.1.113883.10.20.22.2.37 | 2015‑08‑01 |
| CONF:1198‑8404 | |
2.16.840.1.113883.2.51.10.2 | XeH Diagnostic Imaging Report | 2.16.840.1.113883.2.51.10.2 | 2021‑06‑21 14:23:14 |
| CONF:1198‑8795 | |
2.16.840.1.113883.10.20.22.2.37 | Complications Section (V3) | 2.16.840.1.113883.10.20.22.2.37 | 2015‑08‑01 |
| CONF:1198‑8826 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8827 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8828 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8829 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8830 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8833 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8834 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8838 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8839 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8840 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8841 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8842 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8846 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8847 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8849 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8850 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8851 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8853 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8854 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8856 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8857 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8858 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8860 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8861 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8863 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8864 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8866 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8867 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8869 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8870 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8985 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8988 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑8989 | |
2.16.840.1.113883.10.20.22.4.52 | Immunization Activity (V3) | 2.16.840.1.113883.10.20.22.4.52 | 2015‑08‑01 |
| CONF:1198‑9041 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9042 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9043 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9045 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9049 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9050 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9058 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9059 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9060 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9063 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9068 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:1198‑9069 | |
2.16.840.1.113883.10.20.22.4.4 | Problem Observation (V3) | 2.16.840.1.113883.10.20.22.4.4 | 2015‑08‑01 |
| CONF:81‑10398 | |
2.16.840.1.113883.10.20.22.2.16 | Hospital Discharge Studies Summary Section | 2.16.840.1.113883.10.20.22.2.16 | 2015‑08‑13 |
| CONF:81‑10403 | |
2.16.840.1.113883.10.20.22.2.39 | Medical (General) History Section | 2.16.840.1.113883.10.20.22.2.39 | 2015‑08‑13 |
| CONF:81‑10454 | |
2.16.840.1.113883.10.20.6.1.1 | DICOM Object Catalog Section - DCM 121181 | 2.16.840.1.113883.10.20.6.1.1 | 2015‑08‑13 |
| CONF:81‑10487 | |
2.16.840.1.113883.10.20.22.4.31 | Age Observation | 2.16.840.1.113883.10.20.22.4.31 | 2015‑08‑13 |
| CONF:81‑10493 | |
2.16.840.1.113883.10.20.22.4.24 | Drug Vehicle | 2.16.840.1.113883.10.20.22.4.24 | 2015‑08‑13 |
| CONF:81‑10500 | |
2.16.840.1.113883.10.20.22.4.53 | Immunization Refusal Reason | 2.16.840.1.113883.10.20.22.4.53 | 2015‑08‑13 |
| CONF:81‑10518 | |
2.16.840.1.113883.10.20.22.4.6 | Problem Status | 2.16.840.1.113883.10.20.22.4.6 | 2014‑06‑09 |
| CONF:81‑10522 | |
2.16.840.1.113883.10.20.22.4.37 | Product Instance | 2.16.840.1.113883.10.20.22.4.37 | 2015‑08‑13 |
| CONF:81‑10524 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑10531 | |
2.16.840.1.113883.10.20.6.2.9 | Purpose of Reference Observation | 2.16.840.1.113883.10.20.6.2.9 | 2015‑08‑13 |
| CONF:81‑10532 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑10533 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑10918 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑10919 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑15365 | |
2.16.840.1.113883.10.20.22.2.16 | Hospital Discharge Studies Summary Section | 2.16.840.1.113883.10.20.22.2.16 | 2015‑08‑13 |
| CONF:81‑15379 | |
2.16.840.1.113883.10.20.22.2.39 | Medical (General) History Section | 2.16.840.1.113883.10.20.22.2.39 | 2015‑08‑13 |
| CONF:81‑15456 | |
2.16.840.1.113883.10.20.6.1.1 | DICOM Object Catalog Section - DCM 121181 | 2.16.840.1.113883.10.20.6.1.1 | 2015‑08‑13 |
| CONF:81‑15523 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑15524 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑15965 | |
2.16.840.1.113883.10.20.22.4.31 | Age Observation | 2.16.840.1.113883.10.20.22.4.31 | 2015‑08‑13 |
| CONF:81‑15995 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑15996 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑16037 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑16837 | |
2.16.840.1.113883.10.20.22.4.37 | Product Instance | 2.16.840.1.113883.10.20.22.4.37 | 2015‑08‑13 |
| CONF:81‑16850 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑19137 | |
2.16.840.1.113883.10.20.22.4.24 | Drug Vehicle | 2.16.840.1.113883.10.20.22.4.24 | 2015‑08‑13 |
| CONF:81‑19162 | |
2.16.840.1.113883.10.20.22.4.6 | Problem Status | 2.16.840.1.113883.10.20.22.4.6 | 2014‑06‑09 |
| CONF:81‑19164 | |
2.16.840.1.113883.10.20.6.2.10 | Referenced Frames Observation | 2.16.840.1.113883.10.20.6.2.10 | 2015‑08‑13 |
| CONF:81‑19166 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑19172 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑19181 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑26462 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑26463 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑26464 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑26465 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑26466 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑7290 | |
2.16.840.1.113883.10.20.22.5.2 | US Realm Address (AD.US.FIELDED) | 2.16.840.1.113883.10.20.22.5.2 | 2015‑08‑13 |
| CONF:81‑7291 | |
2.16.840.1.113883.10.20.22.5.2 | US Realm Address (AD.US.FIELDED) | 2.16.840.1.113883.10.20.22.5.2 | 2015‑08‑13 |
| CONF:81‑7292 | |
2.16.840.1.113883.10.20.22.5.2 | US Realm Address (AD.US.FIELDED) | 2.16.840.1.113883.10.20.22.5.2 | 2015‑08‑13 |
| CONF:81‑7293 | |
2.16.840.1.113883.10.20.22.5.2 | US Realm Address (AD.US.FIELDED) | 2.16.840.1.113883.10.20.22.5.2 | 2015‑08‑13 |
| CONF:81‑7294 | |
2.16.840.1.113883.10.20.22.5.2 | US Realm Address (AD.US.FIELDED) | 2.16.840.1.113883.10.20.22.5.2 | 2015‑08‑13 |
| CONF:81‑7295 | |
2.16.840.1.113883.10.20.22.5.2 | US Realm Address (AD.US.FIELDED) | 2.16.840.1.113883.10.20.22.5.2 | 2015‑08‑13 |
| CONF:81‑7322 | |
2.16.840.1.113883.10.20.22.4.6 | Problem Status | 2.16.840.1.113883.10.20.22.4.6 | 2014‑06‑09 |
| CONF:81‑7357 | |
2.16.840.1.113883.10.20.22.4.6 | Problem Status | 2.16.840.1.113883.10.20.22.4.6 | 2014‑06‑09 |
| CONF:81‑7358 | |
2.16.840.1.113883.10.20.22.4.6 | Problem Status | 2.16.840.1.113883.10.20.22.4.6 | 2014‑06‑09 |
| CONF:81‑7359 | |
2.16.840.1.113883.10.20.22.4.6 | Problem Status | 2.16.840.1.113883.10.20.22.4.6 | 2014‑06‑09 |
| CONF:81‑7364 | |
2.16.840.1.113883.10.20.22.4.6 | Problem Status | 2.16.840.1.113883.10.20.22.4.6 | 2014‑06‑09 |
| CONF:81‑7490 | |
2.16.840.1.113883.10.20.22.4.24 | Drug Vehicle | 2.16.840.1.113883.10.20.22.4.24 | 2015‑08‑13 |
| CONF:81‑7492 | |
2.16.840.1.113883.10.20.22.4.24 | Drug Vehicle | 2.16.840.1.113883.10.20.22.4.24 | 2015‑08‑13 |
| CONF:81‑7493 | |
2.16.840.1.113883.10.20.22.4.24 | Drug Vehicle | 2.16.840.1.113883.10.20.22.4.24 | 2015‑08‑13 |
| CONF:81‑7494 | |
2.16.840.1.113883.10.20.22.4.24 | Drug Vehicle | 2.16.840.1.113883.10.20.22.4.24 | 2015‑08‑13 |
| CONF:81‑7495 | |
2.16.840.1.113883.10.20.22.4.24 | Drug Vehicle | 2.16.840.1.113883.10.20.22.4.24 | 2015‑08‑13 |
| CONF:81‑7613 | |
2.16.840.1.113883.10.20.22.4.31 | Age Observation | 2.16.840.1.113883.10.20.22.4.31 | 2015‑08‑13 |
| CONF:81‑7614 | |
2.16.840.1.113883.10.20.22.4.31 | Age Observation | 2.16.840.1.113883.10.20.22.4.31 | 2015‑08‑13 |
| CONF:81‑7615 | |
2.16.840.1.113883.10.20.22.4.31 | Age Observation | 2.16.840.1.113883.10.20.22.4.31 | 2015‑08‑13 |
| CONF:81‑7617 | |
2.16.840.1.113883.10.20.22.4.31 | Age Observation | 2.16.840.1.113883.10.20.22.4.31 | 2015‑08‑13 |
| CONF:81‑7618 | |
2.16.840.1.113883.10.20.22.4.31 | Age Observation | 2.16.840.1.113883.10.20.22.4.31 | 2015‑08‑13 |
| CONF:81‑7635 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑7758 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑7760 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑7761 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑7762 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑7763 | |
2.16.840.1.113883.10.20.22.4.32 | Service Delivery Location | 2.16.840.1.113883.10.20.22.4.32 | 2015‑08‑13 |
| CONF:81‑7899 | |
2.16.840.1.113883.10.20.22.4.31 | Age Observation | 2.16.840.1.113883.10.20.22.4.31 | 2015‑08‑13 |
| CONF:81‑7900 | |
2.16.840.1.113883.10.20.22.4.37 | Product Instance | 2.16.840.1.113883.10.20.22.4.37 | 2015‑08‑13 |
| CONF:81‑7901 | |
2.16.840.1.113883.10.20.22.4.37 | Product Instance | 2.16.840.1.113883.10.20.22.4.37 | 2015‑08‑13 |
| CONF:81‑7902 | |
2.16.840.1.113883.10.20.22.4.37 | Product Instance | 2.16.840.1.113883.10.20.22.4.37 | 2015‑08‑13 |
| CONF:81‑7903 | |
2.16.840.1.113883.10.20.22.4.37 | Product Instance | 2.16.840.1.113883.10.20.22.4.37 | 2015‑08‑13 |
| CONF:81‑7905 | |
2.16.840.1.113883.10.20.22.4.37 | Product Instance | 2.16.840.1.113883.10.20.22.4.37 | 2015‑08‑13 |
| CONF:81‑7908 | |
2.16.840.1.113883.10.20.22.4.37 | Product Instance | 2.16.840.1.113883.10.20.22.4.37 | 2015‑08‑13 |
| CONF:81‑7910 | |
2.16.840.1.113883.10.20.22.2.16 | Hospital Discharge Studies Summary Section | 2.16.840.1.113883.10.20.22.2.16 | 2015‑08‑13 |
| CONF:81‑7912 | |
2.16.840.1.113883.10.20.22.2.16 | Hospital Discharge Studies Summary Section | 2.16.840.1.113883.10.20.22.2.16 | 2015‑08‑13 |
| CONF:81‑7913 | |
2.16.840.1.113883.10.20.22.2.16 | Hospital Discharge Studies Summary Section | 2.16.840.1.113883.10.20.22.2.16 | 2015‑08‑13 |
| CONF:81‑8160 | |
2.16.840.1.113883.10.20.22.2.39 | Medical (General) History Section | 2.16.840.1.113883.10.20.22.2.39 | 2015‑08‑13 |
| CONF:81‑8162 | |
2.16.840.1.113883.10.20.22.2.39 | Medical (General) History Section | 2.16.840.1.113883.10.20.22.2.39 | 2015‑08‑13 |
| CONF:81‑8163 | |
2.16.840.1.113883.10.20.22.2.39 | Medical (General) History Section | 2.16.840.1.113883.10.20.22.2.39 | 2015‑08‑13 |
| CONF:81‑8525 | |
2.16.840.1.113883.10.20.6.1.1 | DICOM Object Catalog Section - DCM 121181 | 2.16.840.1.113883.10.20.6.1.1 | 2015‑08‑13 |
| CONF:81‑8530 | |
2.16.840.1.113883.10.20.6.1.1 | DICOM Object Catalog Section - DCM 121181 | 2.16.840.1.113883.10.20.6.1.1 | 2015‑08‑13 |
| CONF:81‑8991 | |
2.16.840.1.113883.10.20.22.4.53 | Immunization Refusal Reason | 2.16.840.1.113883.10.20.22.4.53 | 2015‑08‑13 |
| CONF:81‑8992 | |
2.16.840.1.113883.10.20.22.4.53 | Immunization Refusal Reason | 2.16.840.1.113883.10.20.22.4.53 | 2015‑08‑13 |
| CONF:81‑8993 | |
2.16.840.1.113883.10.20.22.4.53 | Immunization Refusal Reason | 2.16.840.1.113883.10.20.22.4.53 | 2015‑08‑13 |
| CONF:81‑8994 | |
2.16.840.1.113883.10.20.22.4.53 | Immunization Refusal Reason | 2.16.840.1.113883.10.20.22.4.53 | 2015‑08‑13 |
| CONF:81‑8995 | |
2.16.840.1.113883.10.20.22.4.53 | Immunization Refusal Reason | 2.16.840.1.113883.10.20.22.4.53 | 2015‑08‑13 |
| CONF:81‑8996 | |
2.16.840.1.113883.10.20.22.4.53 | Immunization Refusal Reason | 2.16.840.1.113883.10.20.22.4.53 | 2015‑08‑13 |
| CONF:81‑9207 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9208 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9209 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9210 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9213 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9215 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9216 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9219 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9220 | |
2.16.840.1.113883.10.20.6.2.6 | Study Act | 2.16.840.1.113883.10.20.6.2.6 | 2015‑08‑13 |
| CONF:81‑9222 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑9223 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑9224 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑9225 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑9233 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑9235 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑9237 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑9238 | |
2.16.840.1.113883.10.20.22.4.63 | Series Act | 2.16.840.1.113883.10.20.22.4.63 | 2015‑08‑13 |
| CONF:81‑9240 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9241 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9242 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9244 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9246 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9247 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9248 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9250 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9251 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9252 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9253 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9254 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9255 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9257 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9258 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9260 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9261 | |
2.16.840.1.113883.10.20.6.2.8 | SOP Instance Observation | 2.16.840.1.113883.10.20.6.2.8 | 2015‑08‑13 |
| CONF:81‑9264 | |
2.16.840.1.113883.10.20.6.2.9 | Purpose of Reference Observation | 2.16.840.1.113883.10.20.6.2.9 | 2015‑08‑13 |
| CONF:81‑9265 | |
2.16.840.1.113883.10.20.6.2.9 | Purpose of Reference Observation | 2.16.840.1.113883.10.20.6.2.9 | 2015‑08‑13 |
| CONF:81‑9266 | |
2.16.840.1.113883.10.20.6.2.9 | Purpose of Reference Observation | 2.16.840.1.113883.10.20.6.2.9 | 2015‑08‑13 |
| CONF:81‑9267 | |
2.16.840.1.113883.10.20.6.2.9 | Purpose of Reference Observation | 2.16.840.1.113883.10.20.6.2.9 | 2015‑08‑13 |
| CONF:81‑9273 | |
2.16.840.1.113883.10.20.6.2.9 | Purpose of Reference Observation | 2.16.840.1.113883.10.20.6.2.9 | 2015‑08‑13 |
| CONF:81‑9276 | |
2.16.840.1.113883.10.20.6.2.10 | Referenced Frames Observation | 2.16.840.1.113883.10.20.6.2.10 | 2015‑08‑13 |
| CONF:81‑9277 | |
2.16.840.1.113883.10.20.6.2.10 | Referenced Frames Observation | 2.16.840.1.113883.10.20.6.2.10 | 2015‑08‑13 |
| CONF:81‑9279 | |
2.16.840.1.113883.10.20.6.2.10 | Referenced Frames Observation | 2.16.840.1.113883.10.20.6.2.10 | 2015‑08‑13 |
| CONF:81‑9280 | |
2.16.840.1.113883.10.20.6.2.10 | Referenced Frames Observation | 2.16.840.1.113883.10.20.6.2.10 | 2015‑08‑13 |
| CONF:81‑9282 | |
2.16.840.1.113883.10.20.6.2.11 | Boundary Observation | 2.16.840.1.113883.10.20.6.2.11 | 2015‑08‑13 |
| CONF:81‑9283 | |
2.16.840.1.113883.10.20.6.2.11 | Boundary Observation | 2.16.840.1.113883.10.20.6.2.11 | 2015‑08‑13 |
| CONF:81‑9284 | |
2.16.840.1.113883.10.20.6.2.11 | Boundary Observation | 2.16.840.1.113883.10.20.6.2.11 | 2015‑08‑13 |
| CONF:81‑9285 | |
2.16.840.1.113883.10.20.6.2.11 | Boundary Observation | 2.16.840.1.113883.10.20.6.2.11 | 2015‑08‑13 |
| CONF:81‑9304 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑9305 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑9308 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑9309 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑9311 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑9312 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑9314 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑9315 | |
2.16.840.1.113883.10.20.6.2.13 | Code Observations | 2.16.840.1.113883.10.20.6.2.13 | 2015‑08‑13 |
| CONF:81‑9317 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑9318 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑9319 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑9320 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑9324 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑9326 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑9327 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑9328 | |
2.16.840.1.113883.10.20.6.2.14 | Quantity Measurement Observation | 2.16.840.1.113883.10.20.6.2.14 | 2015‑08‑13 |
| CONF:81‑9368 | |
2.16.840.1.113883.10.20.22.5.1.1 | US Realm Person Name (PN.US.FIELDED) | 2.16.840.1.113883.10.20.22.5.1.1 | 2015‑08‑13 |